JOINT FAO/WHO FOOD STANDARDS PROGRAMME

CODEX ALIMENTARIUS COMMISSION

44th Session
Virtual
8 – 13 November 2021

REPORT OF THE 25th SESSION OF THE
CODEX COMMITTEE ON RESIDUES OF VETERINARY DRUGS IN FOODS

Virtual
12 – 16 and 20 July 2021
# TABLE OF CONTENTS

Summary and Status of Work ........................................................................................................ page iii
List of Abbreviations ................................................................................................................ page v
List of CRDs ................................................................................................................................... page vii
Report of the 25th Session of the
Codex Committee on Residues of Veterinary Drugs in Foods ....................................................... page 1

## Paragraphs

Introduction ................................................................................................................................. 1
Opening of the Session ................................................................................................................ 2 - 3
Adoption of the Agenda (Agenda Item 1) ............................................................................. 4 - 5
Matters referred by CAC and other subsidiary bodies (Agenda Item 2) ................................ 6 - 8
Matters of interest arising from FAO/WHO including JECFA (Agenda Item 3.1) .............. 9 – 14
Matters of interest arising from FAO/WHO on feed safety including the Joint FAO/WHO Expert Meeting on Carry-over in Feed and Transfer from Feed to Food of Unavoidable and Unintended Residues of Approved Veterinary Drugs (Agenda Item 3.2) ........................................ 15 – 28
Matters of interest arising from the Joint FAO/IAEA Centre (Agenda Item 3.3) .............. 29 – 31
Matters of interest arising from OIE including VICH (Agenda Item 4) ......................... 32 – 35
Maximum residue limit for Flumethrin (honey) (Agenda Item 5) (Step 7) ..................... 36 – 39
Maximum residue limits for Diflubenzuron (salmon – muscle plus skin in natural proportion): Halquinol (in swine – muscle, skin plus fat, liver and kidney); Ivermectin (sheep, pigs and goats – fat, kidney, liver and muscle) (Agenda Item 6.1) (Step 4) ........................................ 40 – 59
   Diflubenzuron .......................................................................................................................... 42 – 43
   Halquinol .............................................................................................................................. 44 – 50
   Ivermectin .......................................................................................................................... 51 – 59
Maximum residue limits for zilpaterol hydrochloride (cattle fat, kidney, liver, muscle) (Agenda Item 6.2) (Step 4) .................................................................................................................. 60 – 87
Extrapolation of MRLs to one or more species (approach including a pilot on extrapolation on MRLs identified in Part D of the Priority List (Agenda Item 7)) ........................................ 88 – 105
Definition of edible offal for the purpose of harmonization and the elaboration of single MRLs for compounds with dual uses (Agenda Item 8) ................................................................. 106 – 116
Parallel review of a new veterinary drug by JECFA and national regulatory agencies (Agenda Item 9) .......................................................................................................................... 117 - 122
Database on countries’ need for MRLs for veterinary drugs in foods (Agenda Item 10) .......... 123 - 128
Priority list of veterinary drugs for evaluation or re-evaluation by JECFA (Agenda Item 11) ................................................................. 129 – 150
   Part I: Veterinary drugs for inclusion in the priority list for JECFA evaluation/re-evaluation 131 - 146
   Part II: Veterinary drugs for which data availability should be confirmed at CCRVDF26 147
   Part III: Veterinary drugs for which additional data/information is necessary to complete the JECFA evaluation 148
   Part IV: Parallel review - evaluation of a new compound 149
Other business and future work (Agenda Item 12)
   Mitigation of trade impacts associated with the use of environmental inhibitors in agriculture 151
   Issues and concerns that impact the ability of CCRVDF to efficiently perform its work 152
Date and place of next session (Agenda Item 13) ................................................................. 153
Appendices

Appendix I - List of Participants ................................................................. 18

Appendix II - Draft MRL for veterinary drugs in food (Step 8, Step 5/8, Step 5 and Step 4) ......................................................... 38

Appendix III – Amendment to the Procedural Manual:
Risk Analysis Principles Applied by the Codex Committee on Residues of Veterinary Drugs in Foods (adoption) .............. 43

Appendix IV – Amendment to the Glossary of Terms and Definitions (Residues of Veterinary Drugs in Foods (CXA 5-1993) – definition for edible offal (adoption) ................................................................. 45

Appendix V – Principles and approach to the parallel review of a new veterinary drug by JECFA and regulatory agencies (for reference) ................................................................. 46

Appendix VI – Priority list of veterinary drugs requiring approval by CAC (Parts I and V) ................................................................. 47
### SUMMARY AND STATUS OF WORK

<table>
<thead>
<tr>
<th>Responsible Party</th>
<th>Purpose</th>
<th>Text/Topic</th>
<th>Code</th>
<th>Step</th>
<th>Para(s.)</th>
</tr>
</thead>
</table>
| Members and Observers/ CCEXEC81/ CAC44 | Comments/ Adoption | MRLs for:  
- Flumethrin (honey)  
- Diflubenzuron (salmon - muscle plus skin in natural proportion)  
- Halquinol (swine - muscle, skin plus fat, liver and kidney)  
- Ivermectin (sheep, goats, pigs – fat, kidney, liver and muscle) | CX/MRL2 and Database of MRLs and RMRs for residues of veterinary drugs in foods | 8 5/8 | 39, 43, 50, 59 Appendix II |
| CCEXEC81/ CAC44 | Advice/decision | MRLs for zilpaterol hydrochloride (cattle fat, kidney, liver, muscle) | - | 4 | 87, Appendix II |
| Members/ CCEXEC81/ CAC44 | Adoption | Amendment to the Procedural Manual: Risk Analysis Principles applied by CCRVDF - Approach for the extrapolation of MRLs for veterinary drugs to one or more species | Procedural Manual | - | 105, Appendix III |
| Members/ CCEXEC81/ CAC44 | Adoption | Amendment to the Glossary of Terms and Definitions (CXA 5-1993): Definition of edible offal | CXA 5-1993) | - | 116, Appendix IV |
| CCPR52 | Consideration/ Decision | | | | |
| CAC44 (Parts I and V)/ JECFA94 (Parts I, III and IV)/ EWG on Extrapolation (EU) (Part V)/ CCRVDF26 (entire Priority List: Parts I to V) | Approval/ Scientific advice/ Comments/ Consideration | Priority list of veterinary drugs for approval by CAC44 (Parts I and V) | Ongoing work | 1/2/3 | 150, Appendix VI (Parts I and V) |
| Members/ PWG on Priorities (Australia) CCRVDF26 | Comments/ Consideration | Priority list of veterinary drugs for evaluation/re-evaluation by JECFA including veterinary drugs as described in Parts II, III, IV and V | - | - | 150, Appendix VI (Parts II, III, IV and V) |
| CCEXEC81 | Advice | Mechanism for harmonized MRLs setting by CCRVDF and CCPR for compounds with dual uses | | | 150 |
| EWG on Extrapolation (EU)/ CCRVDF26 | Comments/ Drafting/ Consideration | • Extrapolated MRLs for different combinations of compounds/commodities (CRD3) and for ivermectin in goat and sheep’s milk  
• Development of a suitable approach for the extrapolation of MRLs for residues of veterinary drugs for offal tissues | | 105; 150 |
<p>| EWG on edible offal tissues (Kenya and New Zealand)/ CCRVDF26 | Drafting/ Consideration | To work in parallel with the CCPR/EWG-Classification on issues pertaining to harmonization of edible offal (Recommendations 3 – 7 of CX/RVDF 21/25/9) | | 116 |</p>
<table>
<thead>
<tr>
<th>Responsible Party</th>
<th>Purpose</th>
<th>Text/Topic</th>
<th>Code</th>
<th>Step</th>
<th>Para(s.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EWG on criteria for the establishment of action levels (Australia and Canada) CCRVDF26</td>
<td>Drafting/Consideration</td>
<td>Criteria or requirements for the establishment of action levels for unintended or unavoidable carryover from feed to food of animal origin using nicarbazin as a pilot study</td>
<td></td>
<td></td>
<td>150</td>
</tr>
<tr>
<td>CCRVDF</td>
<td>Reference</td>
<td>Principles and approach to the parallel review of a new veterinary drug by JECFA and regulatory agencies</td>
<td></td>
<td></td>
<td>122, Appendix V</td>
</tr>
<tr>
<td>USA and Costa Rica/ Codex Secretariat/ CCRVDF26</td>
<td>Comments/Information Document</td>
<td>Maintenance of the database on countries’ needs for MRLs (ongoing/continuous work)</td>
<td></td>
<td></td>
<td>126 – 127</td>
</tr>
<tr>
<td>New Zealand/ CCRVDF</td>
<td>Information/Consideration in future as needed</td>
<td>Mitigation of trade impacts associated with the use of environmental inhibitors in agriculture</td>
<td></td>
<td></td>
<td>151</td>
</tr>
<tr>
<td>CCRVDF26</td>
<td>Discussion</td>
<td>Issues and concerns that impact the ability of CCRVDF to efficiently perform its work</td>
<td></td>
<td></td>
<td>152</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADI</td>
<td>Acceptable Daily Intake</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALARA</td>
<td>As Low As Reasonably Achievable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMR</td>
<td>Antimicrobial Resistance</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARfD</td>
<td>Acute Reference Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AU</td>
<td>African Union</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bw</td>
<td>Body Weight</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAC</td>
<td>Codex Alimentarius Commission</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCEURO</td>
<td>FAO/WHO Coordinating Committee for Europe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCEXEC</td>
<td>Executive Committee of the Codex Alimentarius Commission</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCLAC</td>
<td>FAO/WHO Coordinating Committee for Latin America and the Caribbean</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCRVDF</td>
<td>Codex Committee on Residues of Veterinary Drugs in Foods</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCPR</td>
<td>Codex Committee on Pesticide Residues</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CIA</td>
<td>Critically Important Antimicrobial Agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CL</td>
<td>Circular Letter</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COP</td>
<td>Code of Practice</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRD</td>
<td>Conference Room Document</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EWG</td>
<td>Electronic Working Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FAO</td>
<td>Food and Agriculture Organization of the United Nations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAP</td>
<td>Good Agricultural Practice</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GEADE</td>
<td>Estimated acute dietary exposure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GECDE</td>
<td>Global Estimated Chronic Dietary Exposure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GL</td>
<td>Guidelines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GMP</td>
<td>Good Manufacturing Practice</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GVP</td>
<td>Good Veterinary Practice</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HACCP</td>
<td>Hazard Analysis and Critical Control Points</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IAEA</td>
<td>International Atomic Energy Agency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFIF</td>
<td>International Feed Industry Federation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JECCA</td>
<td>Joint FAO/WHO Expert Committee on Food Additives</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JMPR</td>
<td>Joint FAO/WHO Meeting on Pesticide Residues</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOAEL</td>
<td>Lowest-Observed-Adverse-Effect Level</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MR</td>
<td>Marker Residue</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRL</td>
<td>Maximum Residue Limit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>No-Observed-Adverse-Effect Level</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OIE</td>
<td>World Organization for Animal Health</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PWG</td>
<td>Physical Working Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROK</td>
<td>Republic of Korea</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPS</td>
<td>Sanitary and Phytosanitary</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRR</td>
<td>Total Radioactive Residue</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UK</td>
<td>United Kingdom</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td>United States of America</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VCIA</td>
<td>Veterinary Critically Important Antimicrobial Agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VICH</td>
<td>International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WG</td>
<td>Working Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WTO</td>
<td>World Trade Organization</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRD No.</td>
<td>Agenda Item</td>
<td>Submitted by</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>--------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01</td>
<td>All items</td>
<td>EU</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Division of Competence between EU and its Member States</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02</td>
<td>11 Report of the EWG/Priorities</td>
<td>WG Chair (Australia)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>03</td>
<td>7 Report of the e-Forum/Extrapolation</td>
<td>e-Forum Chair (EU)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>04</td>
<td>3.2</td>
<td>IFIF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>05</td>
<td>9, 10</td>
<td>Kenya</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>06</td>
<td>8</td>
<td>Colombia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07</td>
<td>6.1, 6.2</td>
<td>HealthForAnimals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08</td>
<td>7</td>
<td>USA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09</td>
<td>2, 3, 4, 5, 6, 7, 8, 9 and 10</td>
<td>Nigeria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>2, 3, 4, 5, 6.1, 7 and 8</td>
<td>Kenya</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>3, 4, 5, 6.1, 7, 8, 9, 10 and 11</td>
<td>Uganda</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>5, 6, 8 and 11</td>
<td>Thailand</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>5, 6, 7 and 8</td>
<td>Morocco</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>11</td>
<td>Philippines</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>3.3</td>
<td>Argentina, Brazil, Chile, Costa Rica, Uruguay, Cuba, Ecuador, Mexico, Panama and Dominican Republic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>6.1, 7, 8, 9 and 11</td>
<td>India</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>5, 6.1, 8 and 9</td>
<td>AU</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>6.2</td>
<td>Ecuador</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>8</td>
<td>ROK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>1, 2, 3, 5, 6, 7, 8, 9 and 10</td>
<td>Senegal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>8</td>
<td>El Salvador</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
INTRODUCTION

1. The Codex Committee on Residues of Veterinary Drugs in Foods (CCRVDF) held its 25th Session virtually, from 12 to 16 and 20 July 2021, at the kind invitation of the Government of the United States of America. Dr Kevin Greenlees, Senior Advisor for Science and Policy, United States Food and Drug Administration, Center for Veterinary Medicine, chaired the session. The session was attended by participants from 72 Member countries, one Member organization and 11 Observer organizations as well as FAO and WHO. The list of participants, including the Secretariats, is given in Appendix I to this report.

OPENING OF THE SESSION

2. The session was addressed by Mr Guilherme Antonio Da Costa, Chairperson of the Codex Alimentarius Commission. Dr Vittorio Fattori and Mr Soren Madsen also provided remarks on behalf of FAO and WHO, respectively.

Division of Competence

3. CCRVDF noted the division of competence between the European Union and its Member States, according to paragraph 5, Rule II of the Procedure of the Codex Alimentarius Commission.

ADOPTION OF THE AGENDA (Agenda Item 1)¹

4. CCRVDF adopted the provisional agenda as the agenda for the Session.

5. CCRVDF also agreed to have a discussion under Agenda item 12 on:
   • Mitigation of trade impacts associated with the use of environmental inhibitors in agriculture.
   • Issues and concerns that impact the ability of CCRVDF to efficiently perform its work.

MATTERS REFERRED BY THE CODEX ALIMENTARIUS COMMISSION AND OTHER SUBSIDIARY BODIES (Agenda Item 2)²

6. CCRVDF noted matters referred by CAC and/or other subsidiary bodies.

7. CCRVDF further noted that the Codex Secretariat would work closely with the Chair of CCRVDF, Chairs of EWGs and the Host Country Secretariat on ways to improve work management of the Committee including the review of the information provided in CX/EXEC 20/78/8.

8. Dr. Yong Ho Park of the Republic of Korea, Chair of TFAMR, informed CCRVDF of the work undertaken by TFAMR on the revision of the Code of Practice to Minimize and Contain Foodborne Antimicrobial Resistance (CXC 61-2005) and the development of the Guidelines on integrated monitoring and surveillance of foodborne antimicrobial resistance. Noting the urgency of the issue of AMR, as it rapidly spreads across the globe, he emphasized the importance of reaching consensus on the two documents in the upcoming TFAMR and asked for continued support in this regard.

MATTERS OF INTEREST ARISING FROM FAO/WHO INCLUDING JECFA (Agenda Item 3.1)³

9. The Representative of FAO summarized the information in the working document and highlighted the activities by JECFA88 (2019), including the recommendations of the JECFA/JMPR Residue Definition Working Group as well as the work on harmonized methodology to assess chronic dietary exposure to residues from compounds used as both pesticides and veterinary drugs⁴.

10. The Representative further highlighted the need for submission of comprehensive data packages to JECFA to allow complete evaluations and recommendations of MRLs. He informed CCRVDF that while published scientific literature may provide evidence that supports the evaluation, JECFA would not be able to use reports that are missing critical information. He further informed how a recent publication⁵ describes some of the challenges for JECFA when sub-optimal and/or incomplete data are provided, and what could be the consequences for the risk assessment.

Microbiological effects on the safety evaluation of veterinary drug residues in food

11. The Representative of WHO noted two end-points of concern for human health that are considered by JECFA: 1) the disruption of the colonization of the human intestinal microbiome and 2) the increase in the population(s) of resistant bacteria in the human intestinal microbiome. CCRVDF further noted the importance of submitting data to evaluate both endpoints.

¹ CX/RVDF 21/25/1
² CX/RVDF 21/25/2
³ CX/RVDF 21/25/3
12. The Representative also introduced the re-organization in WHO that has led to the establishment of a dedicated Division on AMR, and that its activities on antimicrobial resistance in the food chain were now integrated in the work of this division - including WHO’s work in the context of Codex as well as the Tripartite Agreement alongside FAO and OIE. He further highlighted that the FAO/OIE/WHO Tripartite organizations had established a standing Tripartite Joint Secretariat to lead and coordinate the global response to AMR in close collaboration across and beyond the UN organizations.

Other matters

13. CCRVDF paid tribute to Dr Carl Cerniglia, who served as a JECFA Member for many years and was instrumental in the work of the Committee on microbiological assessment of veterinary drug residues.

Conclusion

14. CCRVDF thanked FAO and WHO, and noted the information provided, and that other matters would be considered under the relevant items i.e. Agenda Items 6.1, 8, 9 and 11.

MATTERS OF INTEREST ARISING FROM FAO/WHO ON FEED SAFETY INCLUDING THE JOINT FAO/WHO EXPERT MEETING ON CARRYOVER IN FEED AND TRANSFER FROM FEED TO FOOD OF UNAVOIDABLE AND UNINTENDED RESIDUES OF APPROVED VETERINARY DRUGS (Agenda Item 3.2)6

15. The Representative of FAO summarized the information in the working document and highlighted the activities of FAO and FAO/WHO on feed safety, and in particular presented the outcomes of the Joint FAO/WHO Expert Meeting7 on Carryover in feed and transfer from feed to food of unavoidable and unintended residues of approved veterinary drugs (2019). She also highlighted the recently updated and revised FAO and IFIF manual of Good Practices for the Feed Sector – Implementing the Code of Practice on Good Animal Feeding published in 2020, which includes guidance on carryover.

16. The Committee recalled that CCRVDF23 (2016) had requested FAO and WHO to provide scientific advice and risk management options in order to mitigate the unintended and unavoidable presence of residues of approved veterinary drugs in food of animal origin resulting from carryover of veterinary drugs in feed. Such residues when present in feed could be transferred to food of animal origin and might pose a risk to public health and/or lead to possible trade disruption. In particular, CCRVDF requested scientific advice from FAO and WHO on several aspects of this issue using unexpected residues of lasalocid sodium in eggs as a working example.8

17. The Expert Meeting concluded that in some instances carryover of veterinary drugs was unavoidable to some extent even if the Code of Practice on Good Animal Feeding (CXC 54-2004), GMPs, and HACCP principles were followed, although veterinary drug residues in food following drug carryover in feed are unlikely to be at concentrations high enough to result in human food safety hazard. The Expert Meeting recommended risk management options addressing specific GMPs to prevent/reduce cross-contamination of feed lines including the possible revision of the COP to address specific advice on HACCP-identified control points for carryover during transport from feed mill to farm.

18. The Expert Meeting also considered that an acceptable amount of unavoidable residue of veterinary drug in food of animal origin (i.e. action level) could be established based on residue tolerances in the subsequent food products from exposed animals.

Discussion

19. CCRVDF considered the specific risk management options recommended by the FAO/WHO Expert Meeting in particular whether to revise the COP on good animal feeding to include advice on HACCP-identified points for carryover during transport from feed mill to farm, and whether action levels could be established as an additional risk management measure to ensure that unexpected residues of approved veterinary drugs in non-targeted tissues or food arising from their unintended and unavoidable carryover from feed to food did not pose a risk to human health nor have the potential to create unnecessary barriers to trade.

Code of Practice for the Good Animal Feeding (CXG 54-2004)

20. CCRVDF noted the seven recommendations by the Expert Meeting concerning the COP and discussed whether to include HACCP identified points for carryover during transport from feed mill to farm in the COP (Recommendation 7).

---

6  CX/RVDF 21/25/3–Add.1
7  The report of the Joint FAO/WHO Expert Meeting on Carryover in feed and transfer from feed to food of unavoidable and unintended residues of approved veterinary drugs is available at https://doi.org/10.4060/CA6296EN
8  REP17/RVDF, para. 86
21. A member supported the strengthening of the COP by the inclusion of HACCP-identified points especially at the farm level. However, CCRVDF generally agreed that it was not necessary to amend the COP as it provided sufficient guidance on the control of carryover in feed and transfer from feed to food of unavoidable and unintended residues of approved veterinary drugs, and that the recently revised FAO/IFIF manual published in 2020, provided an excellent guide to implementing the COP.

22. In addition, the Observer from IFIF, indicated that the FAO/IFIF manual included a new and expanded section on the practices countries and individual feed manufacturers could adopt to minimize the risk associated with unavoidable and unintended carryover of veterinary drugs from feed to food, and encouraged Codex members to use this manual to assess and reduce the risk of unavoidable and unintended carryover of approved veterinary drugs in feed.

**Action levels**

23. Delegations in support of the establishment of action levels pointed out that it might be necessary to establish such levels for certain veterinary drugs on a case-by-case basis. These delegations noted that while there was certain evidence of carryover, for example of nicarbazin (which was on the priority list) in chicken eggs, the issue of unavoidable and unintentional carryover was negligible in most cases. Nicarbazin medicated feed for broiler chickens and feed for laying hens can be manufactured at the same feed mills and thus there was the potential for carryover into eggs. Some countries had already set maximum limits for this compound in eggs to cover the unavoidable and unintended carryover residues in the non-target food (eggs). It was thus proposed that CCRVDF might wish to consider establishment of action levels in specific situations where there was evidence of unavoidable/unintended carryover drug in non-target tissues or food, such as the current example of nicarbazin, or to request JECFA to recommend action levels for consideration by CCRVDF. One delegation pointed out that action levels should be based on the ALARA principle, and should only be considered after strengthening the prevention/reduction of cross-contamination of feed by applying the COP and other relevant mitigation measures.

24. Other delegations noted that actions levels were not necessary since the scientific advice showed that issues of unavoidable and unintentional carryover was limited and mainly in eggs, but was unlikely to result in levels high enough to be of public health concern and noted that the implementation of the COP and use of the FAO/IFIF manual and HACCP should be encouraged to avoid or limit unintentional carryover. Therefore, given the limited scope for carryover, there was no need to address the very limited scope for the unintended and unavoidable carryover in feed by setting action levels, nor revising the COP.

25. A concern was raised that, if action levels were established to address the unexpected residues of approved veterinary drugs in foods, due to the unavoidable and unintentional carryover of the drug in feed and its transfer from feed to food resulting in residues in the non-targeted tissue/food of the exposed animal, such levels should clearly describe this situation in order not to imply that such residues could be expected in the food nor that the veterinary drug could be used voluntarily for a purpose different from their registered use.

26. CCRVDF further noted that nicarbazin was on the priority list (Agenda Item 11), and that consideration of actions levels for this compound could be discussed further under that item.

**Conclusion**

**Code of practice on good animal feeding**

27. CCRVDF considered that the provisions in the COP provided sufficient advice to Codex members to address the matter of unavoidable and unintentional carryover of residual levels of veterinary drugs from feed to food. CCRVDF further noted that the other six recommendations, especially those related to strengthening countries capacities to implement the COP/to avoid cross-contamination of feed, complement/support the guidance provided in the COP to member countries. Therefore, no further action from CCRVDF would be required on the Code of Practice on Good Animal Feeding (CXC 54-2004) at present.

**Action levels**

28. CCRVDF noted the recommendations on the establishment of action levels in appropriate edible animal tissues and products, and agreed that the Committee might consider establishing such levels in the future as needed, on the understanding that good feeding practices have been followed in accordance with the Code of Practice on Good Animal Feeding (CXC 54-2004).
MATTERS OF INTEREST ARISING FROM THE JOINT FAO/IAEA CENTRE (Agenda Item 3.3)\(^9\)

29. The Representative of the Joint FAO/IAEA Centre introduced the item and drew attention to recent and ongoing activities implemented by the Joint FAO/IAEA Centre in collaboration with the Member States. The Representative highlighted coordinated research and technical cooperation projects of interest to CCRVDF; the Joint Centre’s work on capacity building; supporting food safety networks and enhancing active participation of developing countries in Codex matters, including research involving the use of radio-labelled material, that could support JECFA evaluations and the process of elaborating prioritized Codex MRLs.

30. Delegations, in particular those from the African and Latin American regions, referring to their written comments, expressed appreciation to the Joint FAO/IAEA Centre for their support and cooperation in strengthening food safety capacities in their countries, in particular their laboratory capacities and development of laboratory networks, which had made significant contributions to improve their food control systems and participation in Codex work. They looked forward to continued and increased collaboration with the Joint FAO/IAEA Centre in the future.

Conclusion

31. CCRVDF thanked the Joint FAO/IAEA Centre, and noted the information provided, including comments made by delegations.

MATTERS OF INTEREST ARISING FROM OIE INCLUDING VICH (Agenda Item 4)\(^10\)

32. The Observer from OIE introduced the item and expressed its willingness to continue the OIE and Codex’s long-standing cooperation in order to promote safe international trade in animals and foods derived from animals. The Observer highlighted the adoption of the OIE’s 7th Strategic Plan (2021-2025) in line with the OIE mission and the publication of the Fifth OIE Annual Report on Antimicrobial Agents Intended for Use in Animals that showed a remarkable decrease of use in antimicrobial agents from 2015 - 2017.

33. The Observer further informed CCRVDF of the OIE’s capacity building activities of the 5th and 6th Cycle Training Seminars worldwide for the OIE Focal Points which addressed a new item: improving access to quality veterinary products and OIE’s continued support for the VICH initiatives.

34. Delegations expressed their appreciation to OIE for their capacity building activities on veterinary drugs in particular in the African region where many countries have become members of the VICH Outreach Forum which would help in improving their capacities in the assessment of veterinary drugs and issuance of marketing authorization. They looked forward to continued and increased collaboration with the OIE in the future.

Conclusion

35. CCRVDF thanked OIE, and noted the information provided, including comments made by delegations.

MAXIMUM RESIDUE LIMIT FOR FLUMETHRIN (HONEY) AT STEP 7 (Agenda Item 5)\(^11\)

36. The Codex Secretariat introduced the item and explained that CAC41 (2018) had adopted the MRL of “unnecessary” for flumethrin in honey at Step 5, that comments at Step 6 had been requested through CL 2020/17-RVDF and compiled in CX/RVDF 21/25/5 and relevant CRDs, and the MRL was for further consideration by CCRVDF.

37. In reply to a question of the interpretation of the MRL of “unnecessary”, the JECFA Secretariat reminded the Committee that it was a risk management decision of CCRVDF considering that the amount of residue of flumethrin that could be expected in honey from the use of Flumethrin in accordance with GVP was very low or not detectable, and unlikely to pose a risk to human health, hence an MRL was considered unnecessary.

38. The Chairperson further recalled that this language came out of CCRVDF in consultation with the JECFA Secretariat based on the very low risk posed by this compound in honey and based on the very low residues found.

Conclusion

39. CCRVDF agreed to advance the MRL of “unnecessary” for flumethrin in honey to CAC44 (2021) for adoption at Step 8 (Appendix II).

---

\(^9\) CX/RVDF 21/25/3-Add.2
\(^10\) CX/RVDF 21/25/4
\(^11\) CX/RVDF 21/25/5 (Argentina, Brazil, Chile, Costa Rica, Cuba, Ecuador, El Salvador, EU, Panama, Peru, Uganda and UK)
40. The Codex Secretariat introduced the item and explained that these are MRL proposals arising from the JECFA88 (2019) evaluations for consideration by CCRVDF at Step 4 following circulation for comments at Step 3 through CL 2021/17-RVDF. Comments in reply to this CL were compiled in CX/RVDF 21/25/6-Add.1 and relevant CRDs.

41. CCRVDF proceeded with the consideration of these MRLs as follows:

**Diflubenzuron**

42. CCRVDF noted general support for the advancement of this MRL for final adoption by CAC44.

**Conclusion**

43. CCRVDF agreed to forward the MRL for diflubenzuron (salmon - muscle plus skin in natural proportion) to CAC44 (2021) for adoption at Step 5/8 (Appendix II).

**Halquinol**

44. Delegations provided the following views:

- The MRLs meet all the procedural and the scientific requirements required for advancement to final adoption by CAC, there are no scientific concerns associated with the use of this compound and its residues in food in accordance with GVP as per the conclusions and recommendations of JECFA88.

- Halquinol is an important tool in combating AMR because it is an authorized therapeutic antimicrobial veterinary drug, for the control and treatment of bacterial enteritis caused by *E.coli* in swine and is not medically important in human medicine.

- Halquinol is a compound used in feed as a dual use, i.e. for therapeutic use to treat diarrhoea in swine and for growth promotion. It is not a critically important antimicrobial for human medicine and its use should be guided by the *Code of Practice to Contain and Minimize Foodborne Antimicrobial Resistance* (CXC 61-2005) and the recommendations of OIE.

- The establishment of MRLs for halquinol would enable competent authorities to supervise its use in swine and its residues in food thus ensuring the safe use of this compound.

- Support for the progress of the MRLs for halquinol and the use in swine as this is an antimicrobial which has not been cataloged as having a potential risk for human health vis-à-vis AMR and it has been reassessed by JECFA88 as being safe for use in swine according to GVP.

- There is no objection to the advancement of halquinol as long as they it is used as an antimicrobial for therapeutic purposes. It was noted that halquinol was not registered in certain countries for use as a growth promoter therefore the registration of halquinol is only for therapeutic use. In addition, countries where edible offals are commonly consumed should adjust these MRLs to take into account the additional intake of these tissues in their countries.

45. The United Kingdom noted that the setting of MRLs for antimicrobials used as growth promoters is incompatible with UK legislation. Therefore, the adoption of the MRLs for halquinol might not be possible according to the current UK legislative framework for the use of growth promoters.

46. The EU therefore expressed its reservation to the establishment of MRLs for halquinol noting that halquinol was an antimicrobial agent, which was indicated for use in pigs and poultry as a growth promoter and for controlling diarrhoea. The EU emphasized that the use of antimicrobial agents was not authorized in the EU for growth promotion, including halquinol, and recalled that the use of antimicrobials for such use did not correspond to a prudent use of antimicrobials, which was necessary to fight antimicrobial resistance. Halquinol was not authorized as a veterinary medicinal product nor as a feed additive in the EU, consequently no MRLs had been established for halquinol in the EU. Norway and Switzerland supported these views and so also expressed their reservation on the establishment of MRLs for this compound.

---

12 CL 2020/17-RVDF; CX/PR 21/15/6 (Argentina, Brazil, Chile, Costa Rica, Cuba, Ecuador, El Salvador, EU, Panama, Peru, Uganda and UK)
47. Morocco indicated its support for the EU’s position. The Delegation further expressed that work on antimicrobials should be consistent across the various CAC subsidiary bodies in particular with the work of the Codex Task Force on Antimicrobial Resistance as the texts developed by TFAMR would guide the use of compounds used as antimicrobials.

48. Egypt expressed its reservation on the establishment of MRLs for halquinol as its use should be linked to therapeutic use and not for growth promotion.

49. An Observer indicated its support to the EU’s position and recognized the value of halquinol as an antimicrobial for therapeutic use. The Observer did not support the use of halquinol as a growth promoter.

**Conclusion**

50. CCRVDF agreed to forward MRLs for halquinol (swine - muscle, skin plus fat, liver and kidney) to CAC44 (2021) for adoption at Step 5/8 (Appendix II) and noted the reservations of the European Union, Norway, Switzerland and Egypt for the reasons expressed in paragraphs 46 and 48.

**Ivermectin**

51. The EU indicated that they had submitted a concern form stating that the proposed MRLs for ivermectin are considerably lower than those established in the EU and, while not representing a consumer-safety concern, they could pose trade difficulties vis-à-vis established GVP. In view of the substantial margin of safety, the EU would propose the review of this compound by JECFA under Agenda Item 11 with a view to setting higher MRLs that are compatible with established GVP in the EU. The Delegation further noted the JECFA Secretariat’s response to their concern form, as explained in CX/RVDF 21/25/6, by which CCRVDF could act as a risk manager and increase the MRL, but indicated that they had identified a sponsor(s) which would provide the relevant data, e.g. labelling information, residue depletion data, etc., to allow JECFA to re-assess the MRLs according to the established procedures in CCRVDF.

52. Delegations generally favored the advancement of the MRLs in the Step Procedure. However, there were split views as to advance the MRLs for final adoption to Step 5/8 or to Step 5 only. In both cases, delegates agreed that if new data became available for JECFA which reflect more updated veterinary practices (i.e. shorter withdrawal periods leading to higher residues that still do not pose health concerns) to conduct the reassessment of this compound, the revised MRLs could be considered by CCRVDF in light of the outcomes of the JECFA review as appropriate.

53. Delegations in favor of progressing the MRLs to Step 5 indicated that this would allow for another round of comments and consideration by CCRVDF in light of the findings of the JECFA review of the EU data, and other data as available, and to decide which MRLs would be more appropriate for CCRVDF to recommend for final adoption by CAC.

54. Some of these delegations expressed their concern on the significant difference between the proposed MRLs for sheep, goats and pigs as compared to those established for cattle for the same tissues, and indicated that JECFA could consider this when reviewing these MRLs as ivermectin was widely used as an external and internal antiparasitic for livestock and humans in their countries, and to also consider the possibility to establish MRLs for additional tissues, e.g. milk, in view of the extensive use of ivermectin in milk-producing species in these countries. In addition, more conservative MRLs would require more sensitive analytical methods for determination of compliance. A delegation indicated that ivermectin was not approved for use in humans in its country.

55. Delegations in support of advancing the MRLs for final adoption at Step 5/8, indicated that this would provide final Codex MRLs for trade as these were internationally traded commodities, while awaiting the outcomes of the JECFA review. CCRVDF would then have the opportunity to revise the adopted MRLs as appropriate based on proposals provided by JECFA. An alternative to this proposal was to reaffirm the MRLs for sheep/goats (fat, liver) as they already exist and to advance the remaining MRLs for sheep/goats/pigs for final adoption to accommodate trade. It was noted that due to the longer meeting intervals of CCRVDF, it would be advisable to advance these MRLs for final adoption to avoid potential trade disruption and that there was no assurance that JECFA could provide revised MRLs for consideration by the next CCRVDF. However, delegations only willing to advance the MRLs to Step 5 indicated that adoption of overly conservative MRLs might also have the potential to create unnecessary technical barriers to trade.

56. Some of these delegations encouraged countries to submit all relevant data available to JECFA to conduct an inclusive assessment to avoid undue delays in the adoption of MRLs for international trade and enquired whether additional data available publicly (e.g. labels which may indicate withholding periods or by (systematic) review of the literature) could supplement the evaluation when only limited datasets have been provided to allow JECFA to carry out the risk assessment. It was noted that this is especially in the case of ivermectin which is a well-known, widely used compound and where different withdrawal periods exist worldwide. If such data were made available JECFA would be able to make a recommendation that reflects the other GVPs as opposed to the 65 days withdrawal period on which the current assessment was based. It was also noted, pending the discussions on the upcoming agenda item, that ivermectin in sheep and goats could be a candidate for extrapolation for MRLs.
57. In reply to the concerns expressed on the significant differences between the MRLs assigned for the same tissues for cattle and sheep/goats/pigs, the WHO JECFA Secretariat noted that the data available was sufficient to establish health guidance values for both toxicological and microbial endpoints (e.g. ADI/ARfD), and that the difference in MRL values for these two sets of commodities resided in large part to the different GVPs used to derived MRLs for cattle (shorter withdrawal period) and sheep/goats/pigs (longer withdrawal periods).

58. In reply to the comments on data available from labels and other sources, the FAO JECFA Secretariat highlighted the importance of submitting all relevant data and information (including residue data and GVPs) in response to the call for data, in order to feed into the JECFA evaluation and ensure an effective and timely process. In addition, the WHO JECFA Secretariat emphasized that it was possible for JECFA to assess only those data that were available to JECFA. In general, residue depletion data should be obtained under conditions consistent with GVP.

Conclusion

59. CCRVDF agreed to forward the MRLs for ivermectin (sheep, goats, pigs – fat, kidney, liver and muscle) to CAC44 (2021) for adoption at Step 5 (Appendix II).

MAXIMUM RESIDUE LIMITS FOR ZILPATEROL HYDROCHLORIDE (CATTLE FAT, KIDNEY, LIVER, MUSCLE) (Agenda Item 6.2)13

60. The Codex Secretariat introduced the item and recalled that the development of MRLs for zilpaterol had been discussed in CCRVDF since 2012 and had been held at Step 4 by CCRVDF since 2016. She further explained that to help discussion, the outcomes of the JECFA81 (2015) and JECFA85 (2017), and the history of the discussions on zilpaterol in CCRVDF, CCEXEC and CAC were summarized in CX/RVDF 21/25/7, including the discussions in CCEXEC and CAC on the implementation of the Statements of Principle and development of guidance for such implementation. CCEXEC will produce guidance to operationalize the Statements of Principle.

61. The Chairperson further reminded the Committee that CCRVDF24 (2018) had expressed strong support for the robust scientific evaluation carried out by JECFA and had emphasized that there were no public health or scientific concerns regarding the proposed MRLs.

62. The Chairperson also drew attention to the Statements of Principle concerning the role of science in the Codex decision-making process and the extent to which other factors are taken into account (Codex Procedural Manual) and noted that the discussion of CCEXEC77 (2019) had been on the application of the Statements of Principle, but that no changes to the Statements had been deemed necessary. He further noted that 3 years had passed in which to find agreement on progressing the MRLs and proposed to first consider whether there was any new scientific information on the safety of zilpaterol to inform the discussions on the MRLs.

63. CCRVDF noted that no new information had been received from any delegation.

64. CCRVDF then proceeded to consider the advancement of the MRLs in the Step process.

65. Delegations against the advancement of the MRLs in the Step Procedure expressed opposition based on the following concerns (some of them also expressed at CCRVDF24):

- Veterinary drugs should not be used for non-therapeutic purposes in food-producing animals.
- There were concerns around exposure to multiple chemicals from multiple food sources and that JECFA evaluations were based on exposure to single compounds only and did not take into account this concern.
- Compounds such as zilpaterol did not belong to sustainable livestock production because of concerns for animal health and welfare.
- By adoption of MRLs for this compound Codex would be sending a signal that the use of zilpaterol and growth promoters in general were acceptable for use in livestock/as a good husbandry practice.
- Zilpaterol and other growth promoters were not authorized for use in their countries and therefore they could not support the MRLs.
- The current MRLs for zilpaterol were for three tissues of cattle (muscle, liver, and kidney). There were several tissues not taken into account by JECFA when considering the consumption patterns in some countries where consumers normally eat other tissues other than kidney, liver and muscle as part of their normal meal. If zilpaterol is administered to food-producing animals, its residues could be distributed through all animal tissues and thus there may be a health concern for consumers. However, no data was provided to support this as zilpaterol was prohibited for use in their countries and was therefore not monitored to contribute to a possible safety assessment by JECFA.

---

13 REP18/RVDF-App. III; CX/RVDF 21/25/7
• Decision on the MRLs should wait until CCEXEC had finalized its discussion on the Statements of Principle and the guidance for its consistent implementation.

• Virtual sessions were not conducive to discussing controversial issues like zilpaterol.

66. Kazakhstan, speaking as Coordinator for CCEURO, pointed out that this was a priority issue for their region and drew attention of CCRVDF to the unanimous views of CCEURO members against the use of growth promoters and the establishment of MRLs for such substances (as expressed at CCEURO30 (2016)14 and CCEURO31 (2019)15).

67. Two delegations, opposed to the advancement of the MRLs, further expressed concern that zilpaterol posed a health risk to humans due to the “huge risk for functional disorders and diseases of the cardiovascular system”. Their studies had shown that the results of JECFA did not take into account people who were already vulnerable and have cardiovascular disease. In response to question from the Chairperson, no data or studies were offered to support this concern.

68. In response to the concerns about the possibility of additive effects from co-exposure to residues of veterinary drugs that share the same mode of action for their pharmacological effects, the JECFA Secretariat informed CCRVDF that JECFA and JMPR had started to pilot an approach to assess this possibility. Therefore, the JECFA Secretariat reassured the Committee that suitable scientific approaches were used for establishing health-based guidance values for individual compounds, while the associated risk assessment could be performed taking into account combined exposure to multiple compounds with similar pharmacological modes of action.

69. Also in response to concerns, the Chairperson informed CCRVDF that the JECFA Secretariat had confirmed that sensitive populations were considered in the evaluation. In relation to the issue of zilpaterol in tissues other than liver, kidney and muscle of cattle, it was clarified that JECFA could only perform an evaluation on those tissues for which suitable data had been submitted to JECFA. The JECFA Secretariat called on members to ensure that for all tissues of relevance to CCRVDF, applicable data are submitted to JECFA.

70. Delegations in favor of progressing the MRLs for zilpaterol in the Step Procedure reiterated similar views to those expressed at CCRVDF24. All of these delegations, barring one, supported advancing the MRLs to Step 5/8. One delegation supporting instead advancing the MRLs to Step 5, proposed this in order to allow another round of comments and discussion.

71. These delegations stated in particular:

• The work of CCRVDF was based on scientific principles and procedures outlined in the risk analysis principles and that all procedures had been duly followed.

• CCRVDF24 had recognized and supported the robust JECFA evaluation, and that this session had confirmed that no relevant new scientific information on the safety of zilpaterol had been made available to the Committee or to JECFA.

• Countries that were opposing the advancement were doing so for reasons outside the Codex mandate.

• Arguments raised by those opposed to advancing the MRLs, such as “their national regulatory frameworks did not allow the use of growth promoters”, were outside the purview of CCRVDF and beyond the Codex mandate. Moreover, taking into account the Statements of Principle, it was emphasized that members that did not support the MRLs could always abstain from acceptance as outlined in the Procedural Manual for precisely such a situation. Several members pointed out their countries had put in reservations on another compound but did not prevent its advancement to Step 5/8.

• No changes to the Statements of Principle were under consideration as per the discussion in CCEXEC and CAC, therefore delaying the decision on the MRLs was not a valid reason to oppose the advancement of MRLs.

• Many countries that had not authorized use of zilpaterol, supported advancement of the MRLs, emphasizing that these MRLs were supported by the science; that due process (all procedures) had been followed for the establishment of the MRLs; no safety concerns associated with the use of zilpaterol had been identified by JECFA based on available data/information; no additional scientific evidence had been made available to CCRVDF or JECFA since the most recent JECFA evaluation; and that the MRLs would help to monitor imports of food from animal origin.

14 REP17/EURO, para. 53
15 REP20/EURO, para. 74
• It was emphasized that many countries rely on Codex standards, and that Codex MRLs have a particularly high utility in settings where national capacities were insufficient to perform risk assessments and establish MRLs. In these circumstances Codex MRLs are essential to ensure public health and fair practices in trade.

• Codex MRLs are recommendations which may be used by any member whether they choose to authorize a product in their country or are looking for a reference to monitor for residues in food.

• CCRVDF, in not advancing this work, is compromising the role of Codex, thus, weakening the multilateral system. It was stressed that even further delaying the adoption of this these standards that had received scientific support would discourage sponsors from submitting data and experts from giving their time and expertise for JECFA assessments, thus, threatening much of the future work of CCRVDF.

72. Ecuador, as Coordinator of CCLAC, drew the attention of CCRVDF to discussions at CCLAC21 (2019) where members strongly supported the establishment of standards, guidelines and other recommendations of Codex based on the principle of risk analysis and sound scientific data, which ensured that factors outside the Codex mandate did not prevent the establishment of standards that ensured the production of safe food, provided the best protection for consumers, and facilitated the application of fair practices in international food trade, and emphasized that it was the science-based nature of Codex standards that underpinned their use as reference standards in WTO SPS Agreement. Therefore, there was strong support to advance the MRLs.

73. A delegation remained neutral on the issue of advancing the MRLs but noted that establishment of such MRLs were incompatible with their national legislation and proposed that all options to reach consensus should be considered.

74. An observer reiterated their view expressed at CCRVDF24 that zilpaterol did not belong in animal husbandry and further noted that healthy animals were important for the production of healthy food and expressed concern that potential synergistic effects with other drugs and toxins had never been evaluated and that consumers would not be aware of its presence in their food. The observer also expressed special concern that zilpaterol is implicated as one cause of bacterial problems in commercial feedlots and that in the view of the observer any zilpaterol standards would not be in alignment with the Environmental, Social and Governance goals set forth in the vet-drug sponsor’s latest ESG Progress Report.

75. Another observer reiterated their views previously expressed and supported the views made by members for the advancement of the MRLs to Step 5/8 noting that there were no safety concerns from a public health perspective, that all processes had been followed and that it was up to CCRVDF come together as a trusted source for science based food standards to protect human health and to facilitate free trade.

76. The Codex Secretary recalled that the issue of zilpaterol and similar topics have occupied Codex for many years taking a huge amount of time of the Commission while very many standards have been successfully set through consensus by Codex due to the excellent work of all members, and it could be asked whether the time spent on this topic was proportional to its importance to protect the health of consumers and ensure fair practices in the food trade. He noted the argument that veterinary drugs should be used only for treatment and not for enhancing production, e.g. growth promotion, and pointed out that the Codex definition for veterinary drugs allowed other uses. With reference to the work on the Statements of Principle, the Secretary reminded CCRVDF that the work undertaken by CCEXEC would not lead to a change to the Statements of Principle as they were not under review. Current work undertaken by the Secretariat was only on guidance for the implementation of the Statements of Principle. This would not lead to a magic solution to the fundamental issue. He reiterated the statement of the Codex Secretariat made at CCRVDF24 (REP19/RVDF, paragraph 46) which offered a solution to the current situation and in particular drew attention to paragraph 4 of the Statements of Principle which stated that “when the situation arises that members of Codex agree on the necessary level of protection of public health but hold differing views about other considerations, members may abstain from acceptance of the relevant standard without necessarily preventing the decision by Codex.”. He also mentioned that other ways used by Codex committees when attempting to find consensus on difficult matters had been included in the document prepared by the Secretariat for CCEXEC77 (CX/EXEC 19/77/10).

Proposals for consideration by CCRVDF for the advancement of the MRLs in the Step Procedure or their continuous retention at Step 4

77. Noting the divergent views, the Chairperson proposed to conclude that the MRLs be advanced to Step 5 while acknowledging the robust risk assessment carried out by JECFA and that while these MRLs posed no public health concerns, members had raised other issues not within the scope and mandate of Codex and CCRVDF. He suggested that members could express reservations, consistent with paragraph 4 of the Statements of Principle.

16 REP20/LAC (Part 2), para. 23
Thailand expressed their reservation to this decision due to the lack of safety assessment for other edible offals and lack of consistency with national laws, as expressed earlier (see paragraph 65). The EU pointed out their objection and not only a reservation to this proposal as they did not believe there was consensus in the room and that advancing the MRLs to Step 5 would signal that there was an agreement on the MRLs and expressed the view that the MRLs should be held at Step 4. China and Russian Federation reiterated their opposition to advancing the MRLs and proposed to retain the MRLs at Step 4. The Russian Federation noted that consensus had not been reached to advance the MRLs. Another delegation reiterated their opposition to advancing the MRLs and proposed that other options should be considered to find consensus and that one option could be to include a note to the MRLs, e.g. such as naming those countries who abstain from acceptance of the MRLs.

In another round of comments to try to reach consensus, the Chairperson proposed to retain the MRLs at Step 4 while he, as Chairperson, would request advice on the way forward from CCEXEC and CAC in view of the lack of consensus.

Those members and one observer who were opposed to advancing the MRLs, supported retaining the MRLs at Step 4. However, those members and one observer in favor of advancing the MRLs opposed this proposal. The United States of America, Brazil, Ecuador, Honduras, Nigeria, Colombia, Costa Rica, Mexico, Kenya, Argentina, Uruguay, Panama, Peru, Chile, Republic of Korea and Japan expressed their reservation to holding the MRLs at Step 4 for the reasons previously stated.

Those delegations in favor of advancing the MRLs proposed as a compromise that CCRVDF reconsider advancing the MRLs to Step 5 to allow another round of comments and discussion and to allow the opportunity for submission of new scientific information should any exist. They further noted that the reasons given for opposing to the advancement of the MRLs did not meet the criteria for consideration in Codex decision-making as set forth in the Procedural Manual, which states that such considerations while they may be legitimate at the national level should not be taken into account in Codex. It would be consistent with the approach previously taken by CCRVDF in advancing other MRLs at this session for those opposing advancement of the zilpaterol MRLs to record their reservations. However, there continued to be diverse views on this point. Those delegations opposed to advancing the MRLs continued to express their opposition, while other delegations in favor of advancing the standard expressed their opposition for not advancing the standard.

After further reflection, the Chairperson stated that, as CCRVDF could not agree to either advance the zilpaterol standard to either Step 5/8, or Step 5 or to retain it at Step 4, there was no conclusion of the Committee for the proposed zilpaterol MRLs and that he as Chairperson would be requesting CCEXEC and CAC to offer guidance on the way forward in view of the lack of consensus.

Those delegations who were opposed to the advancement of the MRLs supported the Chairperson’s proposal. A delegation noted that agreement to put zilpaterol on the priority list was in recognition that the JECFA evaluation could still be used by countries to establish national MRLs. The Chairperson pointed out that objections to including zilpaterol in the priority list had forced CCRVDF to seek guidance from CCEXEC and CAC, and that zilpaterol was included on the priority list based on decisions at CAC35 (2012).

Those delegations who were in favor of advancing the MRLs to Step 5/8, proposed again in a spirit of compromise to advance the MRLs to Step 5 as this would give members another opportunity to provide new scientific evidence. It was reiterated by these delegations that CCRVDF was a technical committee that took into account science and it was CAC that should take a decision on matters outside the remit of the Committee.

Views were expressed that a decision to not progress the MRLs demonstrated a failure to follow the Statements of Principle and would undermine the legitimacy of Codex and as was previously mentioned, could discourage sponsors from submitting data and experts from offering their time and expertise for the scientific risk assessments.

However, CCRVDF continued to be unable to reach consensus.

**Conclusion**

The Chairperson noted that the Committee was unable to reach consensus of either advancing the MRLs to Step 5 or 5/8 or to retain them at Step 4. The Chairperson further noted that all efforts had been exhausted in CCRVDF to reach consensus and the Chairperson observed that CCRVDF had reiterated the views that there are no public health concerns regarding the proposed MRLs and supported the JECFA scientific evaluations while recognizing that some members disagreed. The Chairperson requests CCEXEC81 (2021) to provide a recommendation on the way forward in the framework of the critical review and to inform a CAC decision on the path forward for the MRLs in the Codex step process (Appendix II).
EXTRAPOLATION OF MAXIMUM RESIDUE LIMITS TO ONE OR MORE SPECIES (INCLUDING A PILOT ON EXTRAPOLATION OF MRLs IDENTIFIED IN PART D OF THE PRIORITY LIST (Agenda Item 7)17

88. The European Union, as Chair of the EWG, introduced the item and explained the work done in the EWG and its outcomes and recommendations for (i) proposed principles and approach for the extrapolation and (ii) MRLs using proposed approach that had been piloted to extrapolate MRLs for the veterinary drugs listed in Part D of the priority list (Appendix VI of REP18/RVDF) (10 from the ruminants group and 3 from the fish group). The EWG Chair further explained that further discussions were held through an informal online discussion to consider comments made and to prepare a revised proposal for the procedure for extrapolation (CRD3).

89. The EWG Chair informed CCRVDF that in relation to the extrapolated MRLs, all 10 from the ruminant group could be extrapolated, but only 2 out of the 3 for the fish group. He noted that there was wide support in both the EWG and the informal online discussion group for the proposed approach, but that there were some outstanding issues that needed to be addressed, viz. the grouping of species, a need for authorized use and GVP established in the species to which extrapolation is proposed; and consideration for the need for analytical methods for monitoring purposes. With regard to the grouping of species, it was suggested to group them as ruminants and bony fish, but there were suggestions that these grouping were too broad and instead extrapolating to named species within these groups might be more appropriate.

90. The EWG Chair recalled that the aim of extrapolation was to take full advantage of the scientific evaluations undertaken by JECFA to allow the establishment of maximum safe residues limits in species for which data are unlikely to be forthcoming recognizing that historically CCRVDF had focused on establishing MRLs for substances for which authorized use and GVP already existed.

91. The EWG Chair recommended that CCRVDF consider the revised approach presented in CRD3 so that the Committee could have an approach for the extrapolation of MRLs for species for which no data is available for a JECFA evaluation; and to consider the proposed extrapolated MRLs recommended by the EWG.

92. Costa Rica, as co-Chair of the EWG, expressed their appreciation for the work and emphasized the importance of being able to extrapolate MRLs for species for which no data were available for a JECFA evaluation and how this relates to the possibility to establish MRLs for compounds identified as high priority in the database for countries needs for MRLs for veterinary drugs in foods; and noted that the pilot project was of great importance because of the extraordinary opportunity that it presented to countries, particularly developing countries, to have more MRLs for one or more species available through extrapolation to protect public health and enable trade.

General discussion

93. The discussion focused on the three aspects of the extrapolation criteria: the grouping of species; authorized use and GVP established in the species to which extrapolation is proposed; and consideration for the need for analytical methods for monitoring purposes.

94. There was general agreement on the approach as presented in CRD3. A country expressed its preference for a more conservative approach as originally described in CX/RVDF 21/25/8 as opposed to the revisions made to the criteria for extrapolation in CRD3.

95. Two delegations pointed out that GVP already existed for some of the concerned species and that this shouldn’t concern CCRVDF, but the focus should be on the issue of facilitating international food trade and analytical methods to ensure monitoring; and that the approach should allow for more flexibility (e.g. where extrapolation based on one species could be considered sufficient as was the case for ivermectin under Agenda Item 6.1).

96. A delegation requested clarification on how camels would be considered within the groupings. While camels share characteristics of ruminant animals, they also share some characteristics with non-ruminants. It is unclear whether the metabolism of veterinary drugs in camels would allow extrapolation from species such as cattle. The Chairperson pointed out that in the case of camels, CCRVDF currently lacked the basis for extrapolation and veterinary drugs would have to be considered on a case-by-case basis.

97. Another delegation expressed support for extrapolation of MRLs, but noted that it had been a policy of CCRVDF to elaborate MRLs when a compound had a registered use and established GVP by at least one member country, and that the Risk Analysis Principles applied by CCRVDF stated that registered use and GVP are part of the preliminary risk profile and should be prerequisites for extrapolation to additional species. This was aligned with the purpose of Codex MRLs and ensured that CCRVDF established standards where there was a risk to consumers or trade issues could arise. As this was a new approach for CCRVDF, and to more easily confirm registered uses to justify extrapolation, and in alignment with the comments made on considerations of extrapolations on a case-by-case basis, it was proposed that CCRVDF consider extrapolation to individual species rather than to broad groups of species until more experience is gained, especially for the terrestrial species, including those which may be less closely related.

17 CX/RVDF 21/25/8; CL 2020/42-RVDF; CX/RVDF 21/25/8-Add.1 (Brazil, Ecuador, EU, Japan, Peru, Thailand, Uganda, UK, USA)
98. The Delegation further noted that it would prefer to retain the original criterion by which extrapolation of reference species MRLs to a concerned species on a one-to-one basis should only be considered if the marker residue in the reference species is the parent compound only, as opposed to the same as the total residues of toxicological concern and requested whether the more conservative approach could be retained as a starting point for extrapolation of MRLs for veterinary drugs by looking for a simple solution for the compounds that behaved the best in terms of metabolism and extrapolation.

99. On the point of GVP for the extrapolated MRLs and registered use, a delegate clarified that for off label uses, it might be handled by permits issued by governments or they might be handled by prescription, so it would be hard to sometimes demonstrate good veterinary practice for an application to CCRVDF to extrapolate veterinary drugs. On the point of availability of analytical methods, the delegate further noted that most methods were for multiple residues rather than for a single residue. The delegates supported the introduction of the more pragmatic approach that allowed the possibility to also refer to the total residues of toxicological concern in section 2 as opposed to marker residue in the reference species being only the parent compound.

100. On the point of using only the parent compound (or any of its metabolites) as a marker residue in the reference species, it was noted that the introduction of the possibility to also use the total residues of toxicological concern was in a way a more conservative approach as these were residues of safety concern for consumers that should also be taken into account when considering extrapolation of MRLs for veterinary drugs. This would facilitate the generation of a lot more MRLs in particular for minor species for which it would be unlikely that there would be complete data packages, but there would not likely to be any safety concerns. This approach also reflected current practices applied by food safety regulators in different countries and regions.

Proposed approach

101. CCRVDF considered the revised approach in CRD3 and agreed with the revised approach as presented in CRD3.

102. In addition, CCRVDF agreed to:
   - amend the specific criteria 3 (i) to clarify that when 2 reference species are used, it is acceptable for the MRL for one reference species to have been derived by extension from the other;
   - refer to use the term finfish rather than bony fish and to delete reference to the scientific names as existing Codex MRLs for veterinary drugs mainly apply to finfish;
   - amend the specific Criterion, 3 (i) to make it more flexible by indicating that extrapolation could also be from just one related species under certain circumstances;
   - amend the specific Criterion, 3 (iii), by deletion of the reference to “or approaching 1” as this related to expert judgement, so by deleting this sentence, experts could still accommodate some flexibility in complying with the JECFA practice that the M:T should be equal to 1 when extrapolating MRLs between similar species; and
   - include a note to explain that it was important to harmonize terms for edible tissue as this was important especially in the case of fish and the use of terms muscle and fillet.

103. In reply to a question on the use of the term “extrapolated” vs “extended” MRLs, the EWG Chair clarified that there are cases where JECFA recommends MRLs on the basis of data from a full data package in only one species, but has some comparative metabolism data in a second species that allows JECFA to recommend MRLs in that second species. He further clarified that in this case the appropriate term was extension rather than extrapolation.

Extrapolated MRLs

104. Due to time constraints CCRVDF was unable to consider the proposals for the extrapolated MRLs and agreed that the MRLs would be circulated for comments and further consideration by the EWG.

Conclusion

105. CCRVDF agreed to:
   - (i) forward the approach for extrapolation as revised to CAC44 (2021) for adoption and inclusion as Annex C to the Risk Analysis Principle Applied by CCRVDF (Appendix III);
   - (ii) to include a footnote in paragraph 30, 2nd bullet point of the principles the following: the approach for the extrapolation of MRLs for veterinary drugs to one or more species is presented in Annex C to these principles as a consequential amendment for adoption by CAC44 (Appendix III);
   - (iii) request the Codex Secretariat to issue the proposed extrapolated MRLs for comment through a CL; and
(iv) re-establish the EWG, chaired by the European Union, and co-chaired by Costa Rica, working in English and Spanish to continue discussing the extrapolated MRLs taking into account the comments submitted to the aforementioned CL, and prepare revised proposals for consideration by CCRVDF.

DEFINITION OF EDIBLE OFFAL FOR THE PURPOSE OF HARMONIZATION AND THE ELABORATION OF MAXIMUM RESIDUE LIMITS (Agenda Item 8)

106. Kenya, as Chair of the EWG, introduced the item and proposed to focus the discussion on the recommendations as shown in CX/RVDF 21/25/9. The EWG Chair reminded CCRVDF that the definition for edible offal would help to identify edible offal tissues that were widely consumed and most frequently traded to guide JECFA in the development of MRL recommendations for consideration by CCRVDF. The Committee was also informed that the current definition was developed in the framework of cooperation between CCPR and CCRVDF through the parallel work between the CCRVDF/EWG on edible offal and the CCPR EWG on the revision of the Classification of Food and Feed (CXA 4-1989) for the purpose of harmonization and to facilitate the establishment of single MRLs for compounds with dual uses.

107. CCRVDF agreed to consider the recommendations as follows:

Recommendations 1-2: Definition of edible offal

108. CCRVDF discussed the proposed definition as shown in CX/RVDF 21/25/9 and considered a question on how skin would be treated as there were situations where skin was consumed separately from the muscle, which would be considered as edible offal, and situations where the skin was consumed attached to the muscle/fat, which would not be considered as edible offal, especially for meats potentially consumed with skin such as pork, poultry and fish for which MRLs are usually accompanied by notes indicating e.g. “fat/skin”, “skin + fat” in normal/natural proportion, etc.

109. In order to better describe the situation where skin is considered as edible offal, CCRVDF agreed to amend the definition by indicating that edible offal comprises those parts of the animal considered fit for human consumption apart from the skeletal muscle, fat and attached skin and to incorporate this definition in the Glossary of Terms and Definitions (CXA 5-1993).

110. CCRVDF noted that this definition could lead to inconsistency between the definitions of edible offal in CCRVDF and CCPR, and it was thus agreed to recommend that CCPR also adopt the definition agreed by CCRVDF.

111. In reply to a request to include an explanatory note or footnote to list examples of edible offal that are consumed in each member country, as edible offal might vary depending on local/regional dietary patterns, CCRVDF noted that the definition was kept as broad as possible to remain flexible to cover all possible edible offals that are significantly consumed and traded internationally.

Recommendations 3-6: Classification of food and feed (CXA 4-1989) and Extrapolation of MRLs for edible offal

112. CCRVDF noted that Recommendations 3-6 related to the Classification and extrapolation of MRLs were inter-related and was part of the further collaborative work between CCRVDF and CCPR that could be carried out in parallel between the CCRVDF/EWG on edible offal and the CCPR/EWG on the revision of the Classification.

113. A delegation noted that these recommendations would not preclude CCRVDF from continuing to develop MRLs for the four main tissues “muscle”, “kidney”, “liver” and “fat” in line with established practice in CCRVDF. A default approach could be to set MRLs for “(all) other offal” (other than kidney and liver) as feasible/necessary since other offals generally do not have significant contribution to the dietary intake so an MRL for offal other than kidney/liver would still be human health-protective and could be possibly derived based on extrapolation from the highest residue level in the main offal e.g. liver and/or kidney. Single MRLs for a particular offal (other than kidney and liver) could be set when higher residues could be expected that could pose a risk to human health and there was sufficient data available to set a separate MRL.

Recommendation 7: Harmonized food descriptors to be used by JECFA/JMPR

114. The JECFA Secretariat reminded CCRVDF that it was actually a request from JECFA/JMPR to the EWG to define the terms “fat”, “fat with skin”, “fat/skin”, and “skin” and that it was more a risk management responsibility to provide descriptors rather than that of risk assessors, and therefore descriptors were still needed.

115. CCRVDF noted that this recommendation could be further considered by the EWG.

Conclusion

116. CCRVDF agreed to:

---

18 CX/RVDF 21/25/9; CL 2021/6-RVDF; CX/RVDF 21/25/9-Add.1 (Australia, Chile, Ecuador, Egypt, Iran and Peru)
(i) forward the definition of edible offal as amended by the Committee for inclusion in the Glossary of Terms and Definitions (CXA 5-1993) to CAC44 (2021) for adoption (Appendix IV);

(ii) recommend CCPR to adopt the same definition for consistency and facilitation of establishment of MRLs for compounds with dual purposes; and

(iii) re-establish the EWG, chaired by Kenya, and co-chaired by New Zealand, working in English only to work in parallel with the CCPR/EWG-Classification on issues pertaining to harmonization of edible offal (Recommendations 3 to 7).

PARALLEL REVIEW OF A NEW VETERINARY DRUG BY JECFA AND NATIONAL REGULATORY AGENCIES (Agenda Item 9)19

117. Canada, as Chair of the Electronic Drafting Group, introduced the item and explained that the group had considered the advantages and disadvantages of a parallel approach to compound evaluation based on experience at country level as well as inputs from JECFA. She recalled that the concept of the earlier engagement of JECFA in global joint reviews had been raised as a tool to support the timelier establishment of Codex MRLs for veterinary drugs while mitigating trade risks. The paper outlined the key principles (transparency, confidentiality and independence) that should be followed when undertaking a parallel evaluation and a four-phased process for consideration by CCRVDF. It was noted that this process would shorten time for the establishment and adoption of MRLs from 6 - 9 years as opposed to the current situation of 9 – 12 years. She noted that while no firm MRL had been established through the pilot process, the concept could be considered successful in advancing the risk assessment by JECFA. She proposed that CCRVDF consider the proposed process and its principles and to continue piloting this approach on a case-by-case basis for new compounds seeking registration by national competent authorities.

118. Based on the experience with the evaluation of selamectin at JECFA88 (2019), the JECFA Secretariat offered some considerations regarding the parallel review process. He noted that JECFA remained supportive of this process as it showed the willingness and flexibility from both JECFA and CCRVDF to find new and additional ways to facilitate the development of MRLs in a timely manner. However, the JECFA Secretariat also noted that the principles and requirements for the parallel review approach should be essentially the same as those for a compound that has already received registration in a Member State. This included providing all necessary information required to establish a HBGV and recommend MRLs in the tissue(s) of interest. The JECFA Secretariat further acknowledged that while a finalized GVP may not be available for a product not yet formally approved or registered, proposed dosing regimen(s), withdrawal period(s) etc. should be provided in order to facilitate a JECFA review. This information was necessary for recommending appropriate MRLs.

119. CCRVDF considered the pathway (process) for parallel reviews as outline in CX/RVDF 20/25/10 and noted general support for the principles and the process; that it should be maintained as a tool to speed up development of MRLs. CCRVDF further considered that it was not necessary to include the process for parallel reviews in the Risk Analysis Principles applied by CCRVDF (Procedural Manual) for the reason that prioritization criteria already allowed for it and CCRVDF had historical precedence in this regard, but the Committee should continue with the piloting of parallel evaluations of new veterinary drugs by JECFA and continue to draw from the experience gained with the pilots to further improve the process as needed.

120. An Observer noted that an additional principle that had not been explicitly included in the paper is the “cooperation” between different actors involved in the process of parallel reviews, e.g. JECFA, national/regional competent authorities and sponsors (data submitters), to work in coordination within their respective competences to allow global reviews of new compounds by JECFA and national/regional regulatory agencies for their availability to countries and international trade.

121. On the question whether the process needed further refinement at present, and how veterinary drugs would be identified for inclusion in the pilot (or for parallel review), CCRVDF agreed that further refinement of the process was not necessary at this point in time and that, as evidenced by the pilot on selamectin, the process was flexible enough to adjust to situations that might arise with the assessment of new compounds even if full registration and establishment of GVP at country level had not yet been completed. CCRVDF further agreed that the process for parallel review was but one of the tools to help speed up establishment of MRLs while keeping the integrity and neutrality of the JECFA risk assessment process and that the criteria for inclusion of compounds on the priority list (paragraph12 of the Risk Analysis Principles Applied by CCRVDF – in the Procedural Manual) were sufficient and flexible enough to allow such evaluations.

Conclusion

122. CCRVDF:

---

19 CX/RVDF 21/25/10; CL 2021/5-RVDF; CX/RVDF 21/25/10-Add.1 (Australia, Chile, Cuba, Egypt, EU, Iraq, Iran, Panama, Thailand and HealthForAnimals)
noted the significant advantages shown by the pilot especially with regard to the speed with which Codex MRLs could be developed;

(ii) noted the current prioritization criteria as set out in the Risk Analysis Principles Applied by CCRVDF (Procedural Manual) effectively already allowed for such a process;

(iii) agreed to encourage future compounds that might take advantage of this process; and

(iv) agreed to keep the discussion paper on the principles and approach for parallel review of a new veterinary drug by JECFA and national regulatory agencies available as a reference for the Committee (Appendix V).

DATABASE ON COUNTRIES’ NEEDS FOR MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS IN FOODS (Agenda Item 10)

123. The United States of America, also on behalf of Costa Rica, introduced the item and presented the conclusions and recommendations outlined in the working paper and proposed focusing discussion on the recommendations for the further steps on the use and maintenance of the database on countries’ needs for maximum residue limits for veterinary drugs in foods

124. CCRVDF agreed with the recommendations as presented in paragraphs 11-13 of CX/RVDF 21/25/11 since they provided a structured and transparent way to address countries needs for MRLs and for maintaining the database.

125. Some delegations indicated that the list of compounds in the database could assist countries in generating scientific data and submitting data packages to JECFA in cooperation with the developers of veterinary drugs and thus promoting international cooperation. It was further noted that the compounds identified as “high priority” were actually old compounds that have been in use for many years, especially in developing countries. While these compounds are a priority for assessment by JECFA, there was little incentive for companies to provide data on older drugs and developing countries faced challenges in generating the data required for JECFA to perform the assessment. Thus, collaboration was needed amongst countries and manufacturers to generate or complete the data packages to allow the evaluation of these compounds. These delegations called upon the industry and developed countries to support nomination of such compounds and to assist interested countries with data submission to JECFA in support of the evaluation of these compounds.

Conclusion

126. CCRVDF noted that The United States of America and Costa Rica would continue to maintain and update the database on countries needs as necessary.

127. CCRVDF agreed to recommend that the database on countries’ needs for MRLs for veterinary drugs in foods be made available as a reference document at every session of CCRVDF; and should be available to the Codex Secretariat to accompany the distribution of the CLs requesting comments on the priority list of veterinary drugs for evaluation by JECFA.

128. CCRVDF further agreed to recommend encouraging:

(i) Codex member countries and observer organizations to submit relevant data/information to allow the evaluation of those compound/commodity combinations identified as high priority needs and as feasible starting points for establishment of relevant MRLs; and

(ii) Codex member countries and observer organizations to submit relevant data/information to allow the evaluation of other compound/commodity combinations identified in the database on countries’ needs for MRLs for veterinary drugs.

PRIORITY LIST OF VETERINARY DRUGS FOR EVALUATION OR RE-EVALUATION BY JECFA (Agenda Item 11)

129. Australia, as Chair of the WG which was held virtually on 6 July 2021, introduced the report of the WG, and explained that document addressed new proposals for the priority list; the compound for which data availability would be confirmed by the next session of CCRVDF; compounds for which additional data/information was necessary to complete JECFA evaluations; and compound(s) identified for parallel review(s).

130. CCRVDF considered the recommendations of the WG as presented in CRD2 and took the following decisions:

Part 1: Veterinary drugs for inclusion in the priority list for JECFA evaluation/re-evaluation

131. CCRVDF agreed to include imidacloprid, ivermectin and nicarbazin on the priority list and took the following additional decisions.

---

20 CX/RVDF 21/25/11; CL 2021/2-RVDF; CX/RVDF 21/25/11-Add.1 (Australia, Chile, Egypt, EU, Iraq, Panama, Peru and Thailand)
21 REP18/RVDF, App. VI; CL 2020/18-RVDF; CX/RVDF 21/25/12 (Argentina, Brazil, Costa Rica, Cuba, Iran, Malaysia, Peru, Uganda and USA); CX/RVDF 21/25/12-Add.1 (Brazil and Norway)
Fipronil

Brazil explained that considering the discussions during the WG and due to some other pending issues about the studies that would be made available for submission, the sponsor decided to withdraw the request to include fipronil in the priority list. Noting that fipronil was also being re-evaluated by JMPR, Brazil would wait on that outcome.

Conclusion

CCRVDF agreed to remove fipronil from the priority list.

Ivermectin in goat and sheep milk

In addition to the review of the proposed MRLs for sheep, pigs and goats – fat, kidney, liver and muscle (see Agenda Item 6.1), requests were made for the inclusion of ivermectin MRLs for goats and sheep milk. However, noting that there were no data available, it was proposed that consideration could be given to extrapolate MRLs for ivermectin in goat and sheep milk from the existing MRLs for milk from cattle.

A delegation noted the particular need for MRLs for camels, and asked that this be considered a priority and that CCRVDF provide for extrapolation of MRLs for this species. The Chairperson noted that information was not currently available on how to best extrapolate MRLs for camels, and that such information would need to be developed.

Conclusion

CCRVDF agreed to task the WG on extrapolation to take up this proposal in their discussions.

Nicarbazin

Noting the discussion under Agenda Item 3.2, CCRVDF considered whether action levels for unintended and unavoidable carryover of this drug from feed into eggs could be established and whether it should be included in the priority list. However, at this point, it was unclear what criteria or data would be used to establish such action levels and that such criteria or general requirements needed to be developed first. It was proposed that nicarbazin could be used as a pilot case to facilitate the development of such criteria.

Conclusion

The JECFA Secretariat supported and emphasized the need for additional guidance from CCRVDF to JECFA that might be applicable and necessary to consider for the risk assessment of potential action levels noting the particular importance that CCRVDF, as the risk manager, carefully craft the questions asked of JECFA when seeking risk assessments.

CCRVDF therefore agreed that an EWG chaired by Australia and co-chaired by Canada, working in English only, would prepare a discussion paper on the possible requirements or criteria for developing tolerance levels (action levels) for compounds in tissues due to the unintended or unavoidable carryover of authorized veterinary drugs in feed and their transfer from feed into food of animal origin and to use nicarbazin as a pilot case.

Other matters: Coordination of work between CCPR/CCRVDF and JMPR/JECFA to set single/harmonized MRLs for the same tissue/food for compounds with dual uses

Some delegations raised concerns on the ongoing lack of harmonization on the setting of MRLs for compounds with dual purposes (i.e. use as veterinary drugs and as pesticides). This lack of harmonization sometime led to different ADIs and ARfDs being proposed by JECFA and JMPR, respectively, with resultant differing MRLs for the same tissue/food. These delegations noted that the same toxicological package/data should be used regardless of whether the compound was used as a pesticide or veterinary drug and that the question(s) posed by the risk managers in CCPR and CCRVDF to their respective risk assessment bodies was more important than which expert body did the assessment. Proposals were made for joint JECFA/JMPR reviews for compounds with dual uses and they referred to some joint activities such as the JECFA/JMPR residue definition working group that could assist in this regard.

The Chairperson noted that sponsors provide data to JECFA and JMPR with specific expectations of confidentiality and often, for reasons appropriate and necessary, are often unwilling to share that data outside of the purpose for which it is provided (e.g., to support the health-based guidance value for a pesticide, rather than for a veterinary drug). He then requested that the JECFA Secretariat offer some additional comment.

The WHO JECFA Secretariat clarified that JECFA looked at all relevant information when doing an assessment, including JMPR assessments. In particular, JECFA experts considered the detailed JMPR monographs rather than only relying on the reports which did not always provide detailed information. Using all available information, JECFA came up with its own independent evaluation and established its own health guidance values. He further explained that there was coordination between JMPR and JECFA and that they were looking at common approaches for their work such as evaluation of toxicological information, exposure assessment, etc.
The WHO JECFA Secretariat further clarified that sometimes the ADIs and ArfDs differed because of the large difference in time between evaluations and that data and science might have changed. A solution could be that when a compound is re-evaluated in one committee this should be flagged especially if there is a difference between the ADIs.

The FAO JECFA Secretariat confirmed the confidentiality of might may not be in support of the same substance as a veterinary drug (and vice versa). He further reminded CCRVDF that each expert committee could only act within its scope and it was important for risk managers to forward corresponding questions to the respective scientific meeting/committee. A suitable coordination of requests for scientific advice that would cover dual use compounds beyond the already occurring cooperation on technical issues cannot be achieved through JECFA and JMPR and would need to occur at the level of CCPR and CCRVDF.

The Codex Secretariat explained that currently there were no established procedures or mechanisms in Codex to allow CCPR and CCRVDF to work jointly to establish single/harmonized MRLs for compounds with dual uses and that it might be necessary to request advice from CCEXEC on how CCPR and CCRVDF could work together to address this issue.

Conclusion

CCRVDF agreed to request CCEXEC advice on a mechanism for cooperation between CCPR and CCRVDF on establishment of harmonized MRLs for dual use compounds.

Part II: Veterinary drugs for which data availability should be confirmed at the next CCRVDF

CCRVDF agreed to retain amoxicillin, ethoxyquin and norfloxacin noting that data availability would be confirmed by the next session of the Committee.

Part III: Veterinary drugs for which additional data/information is necessary to complete the JECFA evaluation

CCRVDF noted the continuing JECFA evaluations for ethion, flumethrin and fosfomycin.

Part IV: Parallel review - evaluation of a new compound

CCRVDF noted the continuing parallel review of selamectin.

General Conclusion

CCRVDF agreed to:

(i) forward the priority list of veterinary drugs as amended to CAC44 (2021) for approval (Appendix VI, Parts I and IV);
(ii) establish a PWG, chaired by Australia, working in English, French and Spanish, which would meet immediately before the next session to consider the replies to a CL requesting comments and information on the priority list of veterinary drugs requiring evaluation or re-evaluation by JECFA and other parts of the priority list;
(iii) to request the EWG on extrapolation to consider the extrapolation of MRLs for ivermectin in goat and sheep milk;
(iv) establish an EWG led by Australia and Canada, working in English, to develop a discussion paper on criteria or requirements for the establishment of tolerance levels (actions levels) for unintended or unavoidable carryover from feed to food of animal origin using nicarbazin as a pilot study;
(v) request advice from CCEXEC81 (2021) on possible mechanism for harmonized MRLs setting by CCRVDF and CCPR for compounds with dual uses; and
(vi) request the EWG on Extrapolation to develop a suitable approach for the extrapolation of MRLs for residues of veterinary drugs for offal tissues.

OTHER BUSINESS AND FUTURE WORK (Agenda Item 12)

Mitigation of trade impacts associated with the use of environmental inhibitors in agriculture

CCRVDF noted that the definition for veterinary drug did not exclude those veterinary drugs used solely for environmental purposes. The Committee took note that the future evaluation of such veterinary drugs was consistent with Goal 1 of the Codex 2020-25 Strategic Plan as more and more countries tried to address the impact of animals on climate change.

Issues and concerns that impact the ability of CCRVDF to efficiently perform its work

CCRVDF could not discussed this topic due to lack of time.

DATE AND PLACE OF NEXT SESSION (Agenda Item 13)

CCRVDF noted that the next session was tentatively scheduled to be held in 2023, the final arrangements being subject to confirmation by the Host Country and the Codex Secretariats.
APPENDIX I

LIST OF PARTICIPANTS
LISTE DES PARTICIPANTS
LISTA DE PARTICIPANTES

CHAIRPERSON - PRÉSIDENTE - PRESIDENTA

Dr Kevin Greenlees
Senior Advisor for Science and Science Policy
U.S. Food and Drug Administration
Rockville, MD

CHAIR’S ASSISTANT - ASSISTANTE DU PRÉSIDENT - ASISTENTA DEL PRESIDENTE

Dr Amy-Lynn Hall
Biologist
U.S. Food and Drug Administration
Rockville, MD

MEMBERS NATIONS AND MEMBER ORGANIZATIONS
ÉTATS MEMBRES ET ORGANISATIONS MEMBRES
ESTADOS MIEMBROS Y ORGANIZACIONES MIEMBROS

ANTIGUA AND BARBUDA –
ANTIGUA-ET-BARBUDA –
ANTIGUA Y BARBUDA

Dr Nneka Hull James
Veterinary Officer
Ministry of Agriculture, Land, Housing and the Environment
St. John’s

ARGENTINA – ARGENTINE

Mr Carlos Alli
Head of Delegation
Senasa
Caba

Mr Yamil Alejandro Mattos Villarroel
Ingeniero

BOLIVIA (PLURINATIONAL STATE OF) –
BOLIVIE (ÉTAT PLURINATIONAL DE) –
BOLIVIA (ESTADO PLURINACIONAL DE)

Mr James Deller
Director
Australian Pesticides and Veterinary Medicines Authority (APVMA)

AUSTRIA - AUTRICHE

Mr Thomas W. Kuhn
Head of Institute
Austrian Agency for Health and Food Safety
Vienna

BELGIUM - BELGIQUE - BÉLGICA

Mrs Chantal Rettigner
Expert
FAVV-AFSCA
Brussels

BRAZIL - BRÉSIL – BRASIL

Mrs Suzana Bresslau
Official Veterinarian Inspector
Ministry of Agriculture, Livestock and Food Supply
Brasilia

AUSTRALIA – AUSTRALIE

Dr Dugald Maclachlan
Director, Residues and Microbiological Policy
Department of Agriculture, Water and the Environment
Canberra, ACT

Mr Dzemil Hajric
Director
Food Safety Agency
Mostar

BOSNIA AND HERZEGOVINA - BOSNIE-HERZÉGOVINE -
BOSNIA Y HERZEGOVINA

Mr James Deller
Director
Australian Pesticides and Veterinary Medicines Authority (APVMA)

AUSTRIA - AUTRICHE

Mr Thomas W. Kuhn
Head of Institute
Austrian Agency for Health and Food Safety
Vienna

BELGIUM - BELGIQUE - BÉLGICA

Mrs Chantal Rettigner
Expert
FAVV-AFSCA
Brussels

BRAZIL - BRÉSIL – BRASIL

Mrs Suzana Bresslau
Official Veterinarian Inspector
Ministry of Agriculture, Livestock and Food Supply
Brasilia
Ms Ligia Lindner Schreiner
Regulatory and Health Surveillance Specialist
Brazilian Health Regulatory Agency - ANVISA
Brasília
Ms Angela Maria Queiroz Pellegrino Missaglia
Consultant
Brazilian Feed Manufacturers Association
Brasília
Ms Ester Aguiar
Veterinary Official Inspector
Ministry of Agriculture, Livestock and Food Supply
Brasília
Ms Carolina Araujo Vieira
Health Regulation Expert
Brazilian Health Surveillance Agency - ANVISA
Brasília
Ms Clea Camargo
Regulatory Affairs Senior Manager
ABIQUIFI
São Paulo
Dr Guilherme Antonio Costa Junior
Chair of the Commission
Ministry of Agriculture, Livestock and Food
Mr Carlos Juliano Da Silva
Manager of the Laboratory of Residues and Contaminants in Food
Federal Laboratory of Animal and Plant Health and Inspection, Ministry of Agriculture, Livestock and Supply
Mr Carlos Eduardo De Souza Rodrigues
Federal Inspector
Ministry of Agriculture, Livestock and Food Supply – MAPA
Brasilia
Ms Ivone Delazari
Scientific Researcher
SEARA/ABIA
Mr Wanderson Dos Reis
Regulatory Affairs Manager
Alanac - Association of National Pharmaceutical Laboratories
Ms Bernadete Ferraz Spisso
Head of the Laboratory for Veterinary Drug Residues
Instituto Nacional de Controle de Qualidade em Saúde/Fundação Oswaldo Cruz
Ms Vanessa Gonçalves Dos Santos
Manager of the Laboratory of Residues and Contaminants in Food
Federal Laboratory of Animal and Plant Health and Inspection (LFDA), Ministry of Agriculture, Livestock and Supply
Ms Mary Ane Gonçalves Lana
Federal Inspector
Federal Laboratory of Animal and Plant Health and Inspection (LFDA), Ministry of Agriculture, Livestock and Food Supply
Mr Daniel Rodrigo Hillesheim
Federal Inspector
Ministry of Agriculture, Livestock and Food Supply
Ms Silvana Lima Górmia
Full Professor Pharmacology and Toxicology
Federal Council of Veterinary Medicine/ University of São Paulo – Brazil
Ms Renata Lomele
Technical Specialist – Technical Department
ABIEC – Brazilian Beef Exporters Association
Ms Fatima Machado Braga
Health Regulation Expert
Brazilian Health Regulatory Agency – ANVISA
Brasilia
Mr Luiz Monteiro
Technical Director
Sindan
Ms Gabriela Mura
Marketing & Regulatory Affairs Director
Sindan
Dr João Palermo-Neto
Full Professor
University of São Paulo
São Paulo
Ms Mônica Pinho Cerqueira
Consultant
VIVA LÁCTEOS
Ms Anna Júlia Portz
Technical Assistant (Regulatory Affairs)
VIVA LÁCTEOS
Ms Susanne Rath
Associate Professor
University of Campinas (UNICAMP)
Ms Elenita Rutscheidt Albuquerque
Official Inspector
Ministry of Agriculture, Livestock and Food Supply
Brasilia
Ms Cristina Mara Teixeira
Official Veterinarian
Ministry of Agriculture, Livestock and Supply
Ms Isabela Ávila
Veterinary Products Licensing and Inspection Service (CPV)
Ministry of Agriculture, Livestock and Food Supply

BURKINA FASO
Mr Cyrille Sansan Régis Kambire
Cadre Supérieur/Service du Contrôle Phytosanitaire et de la Qualité des Aliments
Ministère de l’Agriculture
Ouagadougou
Mr Frederic Bationo
Docteur Vétérinaire
Ministry of animal resources
Ouagadougou

Mr Adama Coulibaly
Inspecteur Phytosanitaire et de la Qualité
Ministère de l’Agriculture et des Aménagements Hydro-agricoles
Ouagadougou

Dr Donatien Kabore
Docteur in Food science
Ministère de la Recherche
Ouagadougou

Prof Elie Kabre
Directeur Général du Laboratoire national de santé publique(LNSP)
Ministry of Health
Ouagadougou

Dr Dimitri Meda
Directeur de la toxicologie du contrôle de l’environnement et l’hygiène publique (DTCE/HP) du Laboratoire national de santé publique(LNSP)
Ministry of Health
Ouagadougou

Dr Fulbert Nikiema
Directeur du contrôle des aliments et la nutrition appliquée(DCANA) du Laboratoire national de santé publique(LNSP)
Ministry of Health
Ouagadougou

Dr Gisèle Pare
Director of veterinary services
Ministry of animal resources
Ouagadougou

Mr Yannick Herve Etabi Bikie
Secrétaire Technique CNCOSAC/ Chef de la Cellule des Stratégie de Normalisation
Ministère des Mines de l’Industrie et du Développement Technologique
Yaoundé

CANADA - CANADÁ

Dr Manisha Mehrotra
Director, Human Safety Division
Health Canada
Ottawa

Dr Bhatia Bhim
Sr. Veterinary Drug Reviewer
Health Canada
Ottawa

Dr Guosheng Chen
Scientific Evaluator/Toxicologist
Health Canada
Ottawa

Dr Cole Enns
Doctor
Health Canada
Ottawa

Ms Nancy Ing
Regulatory Policy and Risk Management Specialist
Health Canada
Ottawa

Mr Bryn Shurmer
Section Head, Centre for Veterinary Drug Residues
Canadian Food Inspection Agency
Saskatoon

Mrs Alison Wereley
Senior Policy Analyst
International Affairs Branch, Canadian Food Inspection Agency
Ottawa

Dr Ekaterina Zubkova
Team Leader
Veterinary Drugs Directorate
Ottawa

CHILE – CHILI

Mr Claudio Núñez Contardo
Profesional Subdepartamento de Acuerdos Internacionales
Ministerio de Agricultura
Santiago

Mr Gonzalo Aranda
Profesional Subdepartamento de Acuerdos Internacionales
Ministerio de Agricultura
Santiago
Dr Javiera Cornejo  
Directora de Extensión y Vinculación con el Medio  
Universidad de Chile  
Santiago

Mrs Constanza Peñaloza  
Coordinadora de Registros Sanitarios  
Veterquímica  
Santiago

Mrs Natalia Valerio  
Laboratorio de Residuos de Medicamentos Veterinarios, Química de Alimentos y Nutrición  
Ministerio de Salud  
Mr Diego Varela  
Coordinador Asuntos Internacionales.  
Ministerio de Agricultura.  
Santiago

Mrs Constanza Vergara  
Asesor Técnico  
Ministerio de Agricultura  
Santiago

Mr Fernando Zambrano  
Jefe Subdepartamento Registro y Control de Medicamentos Veterinarios  
Ministerio de Agricultura  
Santiago

Mrs Hanyang Lyu  
Research Assistant  
China National Center for Food Safety Risk Assessment  
Beijing

Mrs Su Ma  
Associate Researcher  
China Institute of Veterinary Drug Control  
Beijing

Dr Hoi Yim Ng  
Veterinary Officer (Risk Assessment)  
Centre for Food Safety, Food and Environmental Hygiene Department, HKSAR Government  
Ms Jing Tian  
Researcher  
China National Center for Food Safety Risk Assessment  
Beijing

Mr Guibiao Ye  
Professor/Director, CCPR Secretariat  
Institute for the control of the Control of Agrichemicals, Ministry of Agriculture and Rural Affairs (ICAMA)  
Beijing

Mrs Yujie Zhang  
Research Assistant Professor  
China Institute of Veterinary Drug Control  
Beijing

Mr Lei Sun  
Associate Researcher  
China Institute of Veterinary Drug Control  
Beijing

Mrs Fengyun Cui  
Senior Engineer  
Science and Technology Research Center of China Customs  
Beijing

Mrs Hao Ding  
Assistant Researcher  
China National Center For Food Safety Risk Assessment  
Beijing

Mr Tao Ding  
Senior engineer  
Animal, Plant and Food Inspection Center, Nanjing Customs District P.R. China  
Nanjing

Mrs Fang Gao  
Deputy Division Director  
Center for Agro-Food Quality & Safety, Ministry of Agriculture and Rural Affairs, P.R.China  
Beijing

Prof Haihong Hao  
Professor  
Huazhong Agricultural University  
Ms Chang Li  
Agronomist  
Center for Agro-Food Quality & Safety, Ministry of Agriculture and Rural Affairs, P.R.China  
Beijing

COLOMBIA – COLOMBIE  
Prof Aida Ivette Rojas Sabogal  
Coordinadora Grupo de registro de Medicamentos y Biológicos de Uso Veterinario y de Farmacovigilancia  
Instituto colombiano Agropecuario  
Bogotá

CROATIA - CROATIE - CROACIA  
Mr Tomislav Kiš  
Head of Sector  
Ministry of Agriculture  
Zagreb
Ms Darija Vratarić  
Senior Adviser  
Ministry of Agriculture  
Zagreb

CUBA

Mr Luis Enrique Jimenez Rodríguez  
Especialista del Departamento de Análisis de Alimentos para el Consumo Animal  
Laboratorio nacional de Higiene de los alimentos/LNHA/Minag  
La Habana

Mr Jorge Félix Medina Pérez  
Secretario Codex Cuba  
Ministerio de Ciencia , Tecnología y Medio ambiente/Citma  
La Habana

Eng Mariana De Jesús Pérez Periche  
Jefe  
Ministerio de la Agricultura  
La Habana

Mr Armando Rafael Romeu Carballo  
Especialista del Departamento de Análisis de Alimentos para el Consumo Animal  
Laboratorio nacional de Higiene de los alimentos/LNHA/Minag  
La Habana

Mrs Susana Sánchez Sanabria  
Jefe del Registro de Productos de uso Veterinario, Presidenta del CTN 96  
Centro Nacional de Sanidad Animal/CENASA/Minag  
La Habana

Mr Modesto Buenaventura Blanco  
Coordinador Normas Alimenticias  
Ministerio de Salud Pública y Asistencia Social (MSP)  
Santo Domingo

Dr Svetlana Afanasieva  
Coordinador  
Ministerio de Salud Pública y Asistencia Social  
Santo Domingo

Mr Rommel Aníbal Betancourt Herrera  
Coordinador General de Inocuidad de Alimentos  
Agencia de Regulación y Control Fito y Zoosanitaria-AGROCALIDAD  
Quito

Mr Lenin Ernesto Moreno Gálvez  
Responsable Gestión de Certificación de Producción Primaria y Buenas Prácticas  
Ministerio de Agricultura y Ganadería  
Quito

Mr Israel Vaca Jiménez  
Analista de certificación de producción primaria y buenas practicas  
Agencia de Regulacion y Control Fito y Zoosanitaria - AGROCALIDAD  
Quito

Ms Daniela Vivero  
Analista de certificación de producción primaria y buenas practicas  
Agencia de Regulación y Control Fito y Zoosanitario - AGROCALIDAD  
Quito

DENMARK - DANEMARK – DINAMARCA

Mrs Elisabeth Okholm Nielsen  
Veterinary Officer DVM PhD Dipl ECPHM  
Danish Veterinary and Food Administration  
Glostrup

DOMINICAN REPUBLIC – DOMINICAIN, RÉPUBLIQUE – DOMINICANA, REPÚBLICA

Mr Abel Jesús Santamaría La Rosa  
Analista Calidad  
Instituto Nacional de Protección de los Derechos del Consumidor, Pro Consumidor  
Santo Domingo

Mr Daniel Vivero  
Analista de certificación de producción primaria y buenas practicas  
Agencia de Regulación y Control Fito y Zoosanitario - AGROCALIDAD  
Quito

ECUADOR - ÉQUATEUR

Ms Leona Nepejchalová  
National expert  
Institute for State Control of Veterinary Biologicals and Medicines  
Brno – Mediánky

Mr Martina Reitharová  
National expert  
Institute for State Control of Veterinary Biologicals and Medicines  
Brno – Mediánky
EGYPT - ÉGYPTE - EGIPTO

Eng Reda Mohamed Sayed Ismail
Food Standards Specialist
Egyptian Organization for Standardization and Quality (EOS)
Cairo

Dr Mona Abdelmeseeh Mankerious Botros
Veterinary Senior
General Organization for Veterinary Services (GOVS)
Giza

Eng Khadeja Elkelany
General Manager Assistant
General Organization for Export and Import Control
Cairo

Dr Gehad Fathy Ahmed Fath Elbab
Head of Researcher and Quality Manager of Food Hygiene
Animal Health Research Institute (AHRI)
Giza

Eng Hanan Fouad Hamid Ibrahim Hashem
Head of Food Standards Department
Egyptian Organization for Standardization & Quality (EOS)
Cairo

Prof Mustafa Abdel Aziz Mohammed
Professor of Pharmacology
Faculty of Veterinary Medicine, Kafr El Sheikh University
Kafr El Sheikh

Dr Lamia Abdou Mohamed Ryad
Head of Researcher and Group Head of Veterinary Drugs
Agriculture Research Center (ARC)
Giza

Dr Marwa Soliman
Technical Manager for Hormones and Veterinary Drugs
Central Public Health Laboratories - Ministry of Health and Populations
Cairo

Eng Mohamed Yassien
Technical Specialist
Egyptian Chamber of Food Industries
Cairo

Dr. Abdefattah Mohamed Ali
Professor of Pharmacology and Toxicology
Faculty of Veterinary Medicine
Suez Canal University
Consultant at National Food Safety Authority

EL SALVADOR

Mrs Claudia Guzmán
Jefe del Punto de Contacto Codex
Organismo Salvadoreño de Reglamentación Técnica
San Salvador

ESTONIA - ESTONIE

Ms Anneli Haugas
Chief Specialist
Ministry of Rural Affairs
Tallinn

Ms Svetlana Jankovenko
Codex Contact Point
Ministry of Rural Affairs
Tallinn

EUROPEAN UNION - UNION EUROPÉENNE - UNIÓN EUROPEA

Mr Risto Holma
Senior Administrator
European Commission
Brussels

Dr Nicholas Jarrett
Administrator
European Medicine Agency
Amsterdam

Ms Judit Krommer
Administrator
European Commission
Brussels

FIJI - FIDJI

Mr Timoci Bogidua
Economic Planning Officer
Ministry of Agriculture
Suva

Mr Jeremaia Koroijiuta
Lab Technician
University of the South Pacific
Suva

Ms Deepika Darshani Lata
Microbiologist
Biosecurity of Fiji
Suva

Ms Keresi Lomata
Senior Veterinary Officer
Ministry of Agriculture

Mrs Elisha Mala
Senior Economic Planning Officer
Ministry of Agriculture
Suva

Ms Lusia Rabaka
Senior Research Officer
Consumer Council of Fiji

Mr Kemueli Seuseu
Food Analyst
Ministry of Agriculture
Suva

Ms Susana Tuivuya
Principal Economic Planning Officer
Ministry of Agriculture
Suva
Ms Nanise Tuqiri  
Principal Research Officer  
Ministry of Fisheries

Mrs Taina Waqaliva  
Senior Food Auditor  
Ministry of Health  
Suva

**FRANCE - FRANCIA**

Mr Jean-Pierre Orand  
Directeur  
ANSES

Mr Tahar Ait Ali  
Directeur  
ANSES

Mr Jean-Luc Angot  
Président du CCGP31  
Ministère de l’agriculture et de l’alimentation  
Paris

Mr Henri Boullier  
Enseignant Chercheur  
INRAE

Mrs Louise Dangy  
Point de contact national  
SGAE  
Paris

Mrs Anne-Marie Jacques  
Expert pharmacologique  
ANSES

Mr Michel Laurentie  
Chef de l’unité « Expérimentation, Modélisation et Analyse de Données »  
ANSES

Mr Eric Verdon  
Adjoint au directeur responsable des activités du laboratoire de référence français et européens pour les RMV  
ANSES

**GAMBIA - GAMBIE**

Dr Abdou Ceesay  
Director General  
Ministry of Agriculture  
Banjul

Mr Mamodou Bah  
Director General  
Food safety and Quality Authority  
Banjul

Dr Ousman Ceessay  
Deputy Director  
Ministry of Agriculture  
Banjul

Dr Essa Jarra  
Principal Veterinary Officer  
Ministry of Agriculture  
Banjul

Ms Lalía Jawara  
Principal Scientific Officer & CCP  
The Food safety and Quality Authority (FSQA)  
Banjul

Mr Momodou Njie  
Director  
Ministry of Fisheries and Water Resources  
Banjul

Mr Babading Sabally  
Director Pharmaceutical Services & AMR Focal Point  
Ministryof Health Central Medical Stores  
Banjul

**GERMANY - ALLEMACNE - ALEMANIA**

Mrs Kristina Ravelhofer-rotheneder  
Head of German Delegation CCRVDF  
Division 326 - Veterinary Medicinal Products, Residues  
Bonn

Dr Anke Finnah  
Scientific Officer  
Federal Office of Consumer Protection and Food Safety (BVL)  
Berlin

Ms Anne Beutling  
Officer  
Federal Ministry of Food and Agriculture  
Berlin

Dr Anja Broenstrup  
Delegate  
Federal Ministry for Food and Agriculture  
Bonn

Dr Joachim Polzer  
Head of Unit  
EU Reference Laboratory for Residues  
BVL - Federal Office of Consumer Protection and Food Safety  
Berlin

Dr Stefan Scheid  
Head of Unit  
Federal Office of Consumer Protection and Food Safety  
Berlin

Mr Niklas Schulze Icking  
Deputy Head of Division  
Federal Ministry of Food and Agriculture  
Berlin

Mr David Schumacher  
Senior Scientific Officer  
German Federal Institute for Risk Assessment  
Berlin

Mrs Hilke Thordsen-böhm  
Delegate  
Federal Ministry of Food and Agriculture  
Berlin
GHANA
Mr Cheetham Lawrence Lartey Mingle  
Principal Regulatory Officer  
Food and Drugs Authority  
Accra

GUYANA
Dr Ozaye Dodson  
Director  
Ministry of Health

HONDURAS
Mrs Maria Interiano  
Coordinadora de Sub Comité sobre Residuos de Medicamentos Veterinarios en los Alimentos  
Veterinarios  
SENASA  
Tegucigalpa  
Ms Maria Eugenia Sevilla  
Asistente Técnico  
Servicio Nacional de Sanidad e Inocuidad Agroalimentaria  
Tegucigalpa

INDIA
Dr K. Abirami  
Assistant Director (Technical)  
FSSAI  
Dr S. C. Dubey  
Assistant Director General (Plant Protection & Biosafety)  
Indian Council of Agricultural Research (ICAR)  
New Delhi  
Mr Perumal Karthikeyan  
Deputy Director  
Food Safety and Standards, Authority of India  
New Delhi  
Dr Iddya Karunasagar  
Chairman  
FSSAI  
Dr Kamran Khan  
Technical Officer  
Export Inspection Agency  
Chennai  
Dr Lokendra Kumar  
Assistant Director (T)  
Export Inspection Agency  
Dr A. K. Mahali  
Deputy Director (T)  
Export Inspection Agency  
Dr Bhaskar Narayan  
Advisor  
Food Safety and Standards Authority of India  
New Delhi

INDONESIA - INDONÉSIE
Dr Nuryani Zainuddin  
Director of Animal Health  
Ministry of Agriculture  
Jakarta  
Dr Diah Aryani  
Food Security Analyst  
Ministry of Agriculture  
Jakarta  
Dr Liys Desmayanti  
Veterinary Office of Veterinary Drug Control  
Ministry of Agriculture  
Jakarta  
Prof Purwiyatno Hariyadi  
Vice Chairperson of the Codex Alimentarius Commission  
Bogor Agricultural University (IPB)  
Bogor  
Dr Ni Made Ria Isriyanti  
Coordinator of Veterinary Drug Control  
Ministry of Agriculture  
Jakarta  
Mrs Sri Bintang Kusumo Winahyu  
Functional Staff of Food Safety Quality Control of Agriculture Products  
Centre of Food Diversification and Food Safety – Food Securi Agency Ministry of Agriculture  
Jakarta  
Mr Aji Barbora Niasono  
Staff  
Ministry of Agriculture  
Jakarta  
Dr Susan Maphilindawati Noor  
Researcher  
Ministry of Agriculture Republic Indonesia  
Bogor

Dr Vijay Pal Singh  
Veterinarian & Assistant Professor (Biological Sciences)  
CSIR-Institute of Genomics and Integrative Biology

Mr Amir Paray  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sakshee Pipliyal  
Assistant Director (Technical)  
Food Safety and Standards Authority of India  
New Delhi

Mr Dhamesh V  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sunaina Verma  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Dr Vijay Pal Singh  
Veterinarian & Assistant Professor (Biological Sciences)  
CSIR-Institute of Genomics and Integrative Biology

Mr Amir Paray  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sakshee Pipliyal  
Assistant Director (Technical)  
Food Safety and Standards Authority of India  
New Delhi

Mr Dhamesh V  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sunaina Verma  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Dr Vijay Pal Singh  
Veterinarian & Assistant Professor (Biological Sciences)  
CSIR-Institute of Genomics and Integrative Biology

Mr Amir Paray  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sakshee Pipliyal  
Assistant Director (Technical)  
Food Safety and Standards Authority of India  
New Delhi

Mr Dhamesh V  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sunaina Verma  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Dr Vijay Pal Singh  
Veterinarian & Assistant Professor (Biological Sciences)  
CSIR-Institute of Genomics and Integrative Biology

Mr Amir Paray  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sakshee Pipliyal  
Assistant Director (Technical)  
Food Safety and Standards Authority of India  
New Delhi

Mr Dhamesh V  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sunaina Verma  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Dr Vijay Pal Singh  
Veterinarian & Assistant Professor (Biological Sciences)  
CSIR-Institute of Genomics and Integrative Biology

Mr Amir Paray  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sakshee Pipliyal  
Assistant Director (Technical)  
Food Safety and Standards Authority of India  
New Delhi

Mr Dhamesh V  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sunaina Verma  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Dr Vijay Pal Singh  
Veterinarian & Assistant Professor (Biological Sciences)  
CSIR-Institute of Genomics and Integrative Biology

Mr Amir Paray  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sakshee Pipliyal  
Assistant Director (Technical)  
Food Safety and Standards Authority of India  
New Delhi

Mr Dhamesh V  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi

Ms Sunaina Verma  
Technical Officer  
Food Safety and Standards Authority of India  
New Delhi
Mrs Theista Savanty  
Secretariat of the Codex Contact Point of Indonesia  
National Standardization Agency of Indonesia  
Jakarta

Dr Bess Tiesnamurti  
Researcher  
Indonesian Centre for Animal Research and Development  
Bogor

Dr Fadjar Sumping Tjatur Rasa  
Senior Veterinarian  
Ministry of Agriculture  
Jakarta

Dr Yeni Widiawati  
Researcher  
Indonesia Research Institute for Animal Production (IRIAP)  
Bogor

IRAN (ISLAMIC REPUBLIC OF) -  
IRAN (REPUBLIQUE ISLAMIQUE D') -  
IRÁN (REPÚBLICA ISLÁMICA DEL)

Dr Alireza Babapour  
Member National Committee of CCRVDF  
Iran Veterinary Organization  
Tehran

Dr Ehsan Zaerzadeh  
Secretary, National Codex Committee of CCRVDF  
Institute of Standards & Industrial Research of Iran  
Tehran

IRELAND - IRLANDE - IRLANDA

Mr William Fitzgerald  
Senior Veterinary Inspector  
Department of Agriculture Food and the Marine (DAFM)

ITALY - ITALIE - ITALIA

Mr Giulio Cardini  
Senior Officer  
Ministero Politiche Agricole Alimentari e Forestali e del Turismo  
Rome

Mr Salvatore Macri  
Official  
Ministry of Health  
Roma

JAMAICA - JAMAÏQUE

Mr Errol Dakin  
Toxicologist/Analyst  
Ministry of Agriculture  
Kingston

JAPAN - JAPON - JAPÓN

Mr Shinnosuke Miki  
Assistant Director  
Ministry of Health, Labour and Welfare

Dr Kei Iwata  
Associate Director  
Ministry of Agriculture, Forestry and Fisheries  
Tokyo

Dr Takashi Kozasa  
Associate Director  
Ministry of Agriculture, Forestry and Fisheries  
Tokyo

Ms Marie Ohara  
Technical Officer  
Ministry of Health, Labour and Welfare  
Tokyo

Dr Takatoshi Sakai  
Senior Researcher  
National Institute of Health Sciences  
Kanagawa

Ms Takako Yano  
Deputy Director  
Food Safety Commission  
Tokyo

Ms Aya Tanaka  
Staff  
Ministry of Agriculture, Forestry and Fisheries

Ms Hiroki Yanagisawa  
Section Chief (Aqua drugs)  
Ministry of Agriculture, Forestry and Fisheries (MAFF)

KAZAKHSTAN - KAZAJSTÁN

Dr Nailya Karsybekova  
Regional Coordinator CCEURO  
Ministry of Healthcare the Republic of Kazakhstan  
Astana

Mr Zeinulla Sharipov  
expert on veterinary and phytosanitary, KZ Codex Team  
Ministry of Healthcare the Republic of Kazakhstan  
Astana

KENYA

Mr Allan Azegele  
Deputy Director  
Ministry of Agriculture, Livestock & Fisheries

Mr George Kiminza  
Food Standards Officer  
Kenya Bureau of Standards  
Nairobi

Mr Leonard Kimtai  
Food Safety Officer  
Ministry of Health, Food Safety Unit

Ms Maryann Kindiki  
Manager, National Codex Contact Point  
Kenya Bureau of Standards  
Nairobi
Mr Kimutai Maritim
Deputy Director
Ministry of Agriculture, Livestock & Fisheries
Nairobi

Ms Lucy Namu
Head Analytical Chemistry Laboratory and Food Safety
Kenya Plant Health Inspectorate Services
Nairobi

Lao People’s Democratic Republic - Laos
Dr Phouth Inthavong
Deputy Director General
Ministry of Agriculture and forestry
Vientiane capital

Dr Santi Kongmany
Director
National University
Vientiane capital

Mrs Viengxay Vansilalom
Deputy Director General
Ministry of Health
Vientiane capital

Latvia - Lettonie - Letonia
Mrs Baiba Karklina
Deputy head of Division
Ministry of Agriculture of Latvia
Riga

Lebanon - Liban - Líbano
Dr Mariam Eid
Agro Industries Service
Ministry of Agriculture

Malaysia - Malaisie - Malasia
Dr Rohaya Mohd Ali
Senior Director
Ministry Of Agriculture And Food Industry

Prof Dr Arifah Abdul Kadir
Head of Department
University Putra Malaysia

Mrs Nor Fasihah Mohd Sani
Senior Research Officer
Department of Veterinary Services Malaysia

Mr Sudirman Awaludin
Chemist
Dept of Chemistry Malaysia

Dr Liung Wun Chee
Chair for VPR, VAM
MAVMA

Ms Sharon Chua
EXCO
Malaysian Animal Health and Nutrition Industries Association (MAHNTA)

Ms Alifah Ismail
Head of Veterinary Medicine and Biologics Section
Dept. of Veterinary Services, Malaysia

Dr Tariq Jaafar
Veterinary Officer
Dept. of Veterinary Services, Malaysia

Dr Muhammad Nazri Khairuddin
Head of Veterinary Medicine and Biologics Unit
Dept. Of Veterinary Services, Malaysia

Ms Nor Azmina Mamat
Assistant Director
Ministry of Health Malaysia
Wilayah Persekutuan Putrajaya

Dr Marzura Md Rodzi
Veterinary Officer
Department of Veterinary Services, Malaysia

Dr Yusniiza Mohd Yusof
Chief Assistant Director
Ministry of Agriculture and Food Industry

Ms Shazlina Mohd Zaini
Principal Assistant Director
Ministry of Health Malaysia
Putrajaya

Ms Zarina Zainuddin
Fisheries Officer
Department of Fisheries, Malaysia

Mexico - Mексique – México
Ms María Elena González Ruiz
Directora de Servicios y Certificación Pecuaria
SENASICA

Mrs Macarena Hernández Márquez
Directora General del Consejo Mexicano de la Carne
COMECA

Ms Mireya Ortiz Nicoli
Jefa de Departamento de Mantenimiento de la
Certificación en instalaciones animales, procesos y
productos
SENASICA

Ms Lorena Reyes Guerra
Subdirectora de Regulación de Establecimientos y
Productos Veterinarios
SENASICA

Mrs Mildred E. Villanueva Martínez
Vicepresidente de Normalización y Sustentabilidad del
Consejo Mexicano de la Carne
COMECA

Mrs Nubia Villasana Santana
Subdirectora de Apoyo a la Sanidad e Inocuidad Acuícola
y Pesquera
SENASICA

Estado de México

Morocco - Maroc - Marruecos
Dr Samir Dakaoui
Head of Pharmacy and veterinary Inputs
ONSSA
Rabat
Dr Hind Ahabchane
Adhérente à ANPV
Association Nationale des Sociétés Pharmaceutiques Vétérinaires (ANPV)
Casablanca

Dr Nisrine Chokri
Adhérente à ANPV
Association Nationale des Sociétés Pharmaceutiques Vétérinaires (ANPV)
Casablanca

Dr Hind Ibbou
Adhérente à ANPV
Association Nationale des Sociétés Pharmaceutiques Vétérinaires (ANPV)
Casablanca

Mrs Khadija Kadiri
Chef de Service de la Normalisation et du Codex Alimentarius
Office National de la Securite Sanitaire des Produits Alimentaires
Rabat

Dr Samah Tahri
Veterinarian
ONSSA
Rabat

MOZAMBIQUE
Dr Maria Luiz Fernandes
Senior Governmental Officer
Govt Mozambique

NETHERLANDS - PAYS-BAS - PAÍSES BAJOS
Mrs Susanne Waelen
Senior Policy Officer
Ministry of Agriculture, Nature and Food Quality
The Hague

Mr Jelle Van Meer
Senior Policy Officer
Ministry of Agriculture, Nature and Food Quality
The Hague

NEW ZEALAND - NOUVELLE-ZÉLANDE - NUEVA ZELANDIA
Ms Awilda Baoumgren
Specialist Adviser
Ministry for Primary Industries

Ms Karen Booth
Manager
The Ministry for Primary Industries

Mr Warren Hughes
Principal Adviser ACVM
Ministry for Primary Industries
Wellington

Mr Bill Jolly
Chief Assurance Strategy Manager
Ministry for Primary Industries
Wellington

Mr Raj Rajasekar
Senior Programme Manager
Codex Coordinator and Contact Point for New Zealand
Wellington

Ms Lisa Ralph
Senior Policy Analyst
Ministry for Primary Industries

NIGERIA - NIGÉRIA
Prof Reuben Arowolo
Professor of Pharmacology
Federal University of Agriculture

Dr Mabel Kamweli Aworh
Assistant Director
Federal Ministry of Agriculture & Rural Development
Abuja

Mr Ibrahim Attai Isah
Assistant Director
National Agency for Food and Drug Administration and Control (NAFDAC)
Lagos

Dr Mairo Gujba Lawan Kachalla
Principal Veterinary Officer
Federal Ministry of Agriculture and Rural Development
Abuja

Mr Papa’a Johnson Pongri
Assistant Chief Standards Officer
Standards Organisation of Nigeria
Abuja

Dr Bukar Ali Usman
Director
National Agency for Food and Drug Administration and Control
Lagos

NORWAY - NORVÈGE - NORUEGA
Mrs Christine Børnes
Senior Adviser
Norwegian Food Safety Authority
Bergen

Mrs Vigdis S. Veum Møllersen
Senior Adviser
Norwegian Food Safety Authority
Oslo

PANAMA - PANAMÁ
Eng Joseph Gallardo
Ingeniero en Alimentos / Punto de Contacto Codex
Ministerio de Comercio e Industrias
Panamá

Dr Jezibel Donado Arosemena
Jefa del Departamento de Registro de la DINASA-MIDA
Direccion Nacional de Salud Animal
Panama

Ms Katerin Adela Gaitan Vega
Analista de Alimentos y Bebidas
Universidad de Panamá
Panama
Dr Anarella Jaén De Merón  
Médico Veterinario  
Ministerio de Salud  
Panama

Mrs Carmen Peralta  
Analista Técnica del Departamento de Trámite de Importación y Exportación de la Dirección Nacional de Salud Animal  
Ministerio de Desarrollo Agropecuario  
Panamá

Mr Eric Trejos Valencia  
Jefe de laboratorio de Residuos Toxicos en Productos Carnico  
Dirección Nacional de Salud Animal  
Panama

PAPUA NEW GUINEA - PAPOUASIE-NOUVELLE-GUINÉE - PAPUA NUEVA GUINEA

Mr Elias Taia  
Program Manager  
Department of Agriculture & Livestock  
Port Moresby

PARAGUAY

Mr Oscar Iglesias Benítez  
Coordinador de Comité  
Servicio Nacional de Calidad y Salud Animal - SENACSA  
Asunción

Ms Maria Ines Ibarra  
Codex Contact Point of Paraguay  
Asunción

PERU - PÉROU - PERÚ

Ms Maria Magdalena Francia Marchena  
Especialista de la Subdirección de Inocuidad Agroalimentaria/Coordinadora Titular de la CT de Residuos de Medicamentos Veterinarios  
SENASA  
La Molina

Ms Noemi Diana Arauco Mayorga  
Evaluador de la Subdirección de Habitaciones Pesqueras y acuícolas  
SANIPES  
Lima

Mr Renzo Felipe Chaupis Calderón  
Inspector Sanitario de la Subdirección de Supervisión Acuícola  
SANIPES  
Lima

Mrs Amparo Pilar Cuadros Meza  
Especialista de la Subdirección de Inocuidad Agroalimentaria/Coordinadora de la CT de Residuos de Medicamentos Veterinarios  
SENASA  
La Molina

PHILIPPINES - FILIPINAS

Ms Danica Dimaya  
Chemist III  
National Meat Inspection Service  
Department of Agriculture  
Quezon City

Dr Alicia Layson  
PH National Focal Point on AMR for OIE  
Bureau of Animal Industry  
Department of Agriculture  
Quezon City

Dr Chester Joshua Saldaña  
Food and Drug Regulatory Officer IV  
Food and Drug Administration – Common Services Laboratory  
Muntinlupa City

Dr Alpha Mateo-Ilanuza  
Senior Science Research Specialist  
Bureau of Agriculture and Fisheries Standards  
Quezon City

Dr Sonia Somga  
Supervising Science Research Specialist  
Bureau of Agriculture and Fisheries Standards  
Quezon City

Mr Hernando  
Agriculturist I  
Bureau of Animal Industry  
Department of Agriculture  
Quezon City

PORTUGAL

Ms Inês Almeida  
Head of Unit  
Directorate-General for Food and Veterinary (DGAV)  
Lisboa

Mrs Andreia Alvarez Porto  
Permanent Representation of Portugal to the EU

Mr Miguel Cardo  
Deputy Director-General  
Directorate-General for Food and Veterinary (DGAV)  
Lisboa
Dr Luísa Ramalho  
Senior Technician  
Directorate-General for Food and Veterinary (DGAV)  
Lisboa

REPUBLIC OF KOREA – 
RÉPUBLIQUE DE CORÉE – 
REPÚBLICA DE COREA

Mrs Ji-yoon Jeong  
Deputy Director  
Ministry of Food and Drug Safety

Dr Sang-hee Jeong  
Professor  
Hoseo University

Ms Soyoung Lee  
Researcher  
Ministry of Agriculture, Food and Rural Affairs

Mr Sang-mok Lee  
Scientific Officer  
Ministry of Food and Drug Safety

Mr Ji-hoon Lee  
Junior researcher  
National Institute of Fisheries Science, Ministry of Oceans and Fisheries

Ms Yeo-jin Min  
Researcher  
Ministry of Food and Drug Safety

Mrs Se-jong Park  
Scientific Officer  
Ministry of Food and Drug Safety

Dr Su-jeong Park  
Scientific Officer  
Ministry of Food and Drug Safety

Dr Yong-ho Park  
Professor (Chairperson, Codex TFAMR)  
Seoul National University

Mr Jung Soo Seo  
Senior Researcher  
National Institute of Fisheries Science, Ministry of Oceans and Fisheries

Ms Jeonghwa So  
Deputy Director  
Ministry of Oceans and Fisheries

Ms Hyun Kyung Woo  
Codex researcher  
Ministry of Food and Drug Safety

Ms Jihye Yang  
SPS Researcher  
Ministry of Oceans and Fisheries

Mrs Hee Yi  
Researcher  
Animal and Plant Quarantine Agency  
Gimcheon-si

ROMANIA - ROUMANIE - RUMANIA

Ms Oana Dinca  
Counselor  
National Sanitary Veterinary and Food Safety Authority  
Bucharest

RUSSIAN FEDERATION – 
FÉDÉRATION DE RUSSIE – 
FEDERACIÓN DE RUSIA

Ms Ksenia Bokovaya  
Head of the Division  
Federal Service for Surveillance on Consumer Rights  
Protection and Human Well-being  
Moscow

Ms Olga Fomicheva  
Division Counselor  
Federal Service for Surveillance on Consumer Rights  
Protection and Human Wellbeing (Rospotrebnadzor)  
Moscow

Mr Alexander Konstantinov  
Expert chemist  
FBUZ "Federal Center for Hygiene and Epidemiology”  
Rospotrebnadzor  
Moscow

Ms Anna Koroleva  
Consultant  
Federal Service for Surveillance on Consumer Rights  
Protection and Human Well-being  
Moscow

Ms Irina Semenova  
Head of laboratory - expert chemist  
“Federal Hygienic and Epidemiological Center” of Rospotrebnadzor  
Moscow

Ms Tatiana Zavistyaeva  
Deputy Chief  
Clinic FBUN "FIZ Food and Biotechnology"  
Moscow

SENEGAL - SÉNÉGAL

Dr Chantal Biagui  
Chef De Bureau  
Direction Des Services Veterinaires  
Dakar

Dr Fatoumata Barry  
Expert SSA  
UCAD

Dr Raphaël Coly  
Expert SSA  
Comite National Codex  
Dakar

Mr Abdoulaye Diawara  
Inspecteur Technique  
Ministère de l’Elevage et des Productions Animales  
Dakar

Dr Alioune Badara Kane Diouf  
Chef De Bureau  
Direction Industries de Transformation de Peche
Prof Amadou Diouf
Président du Comité national du Codex Alimentarius
Ministère de la Santé et de l’Action sociale
Dakar

Mrs Mame Diarra Leye
Point De Contact National
Direction Générale de la Santé
Dakar

Mrs Astou Ndiaye
Chef d’unité
Laboratoire National D’Analyses et de Contrôle
Dakar

Dr Youga Niang
Charge de Recherche
Institut Senegalais de Recherche Agricole
Dakar

Dr Moutar Seydi
Chef du Bureau Pharmacie Veterinaire
Direction des Services Veterinaires
Dakar

Dr Assiongbon Teko-Agbo
Enseignant Chercheur
EISMV

SINGAPORE - SINGAPOUR - SINGAPUR

Dr Ping Shen
Branch Head
Singapore Food Agency

Ms Lifei Huang
Senior Scientist (Drugs & Residues)
Singapore Food Agency

Ms Guat Shing Teo
Specialist Team Lead (Drugs & Residues)
Singapore Food Agency

Dr Yuansheng Wu
Director
Singapore Food Agency

SLOVAKIA - SLOVAQUIE - ESLOVAQUIA

Dr Judita Hederová
Director
Institute for State Control of Veterinary Biologicals and Medicaments
Nitra

Dr Martina Ihnátová
Head of the Department
State Veterinary and Food Administration of the Slovak Republic
Bratislava

SLOVENIA - SLOVÉNIE - ESLOVENIA

Mr Mitja Šedlbauer
Veterinary and Food Safety Counsellor
Ministry of Foreign Affairs
Brussels

Ms Outi Tyni
Political Administrator
Council of the European Union, General Secretariat
Bruxelles

Ms Vida Znoj
Head of Food, Feed and Veterinary Medicinal Products Division
Administration for food safety, veterinary sector and plant protection
Ljubljana

SOUTH AFRICA - AFRIQUE DU SUD - SUDÁFRICA

Dr Mphane Molefe
Director: Veterinary Public Health
Department of Agriculture, Forestry and Fisheries
Pretoria

Mrs Penny Campbell
Director: Food Control
Department of Health
Pretoria

Dr Alice Sigobodhla
Manager
South African Health Products Regulatory Authority
Pretoria

SPAIN - ESPAGNE - ESPAÑA

Ms Gema Cortes Ruiz
Jefe de Servicio del Departamento de Medicamentos Veterinarios
Ministerio de Sanidad
Madrid

Ms María Hernández Nieves
Jefa de Sección
Ministerio de Agricultura, Pesca y Alimentación (MAPA)
Madrid

Mr Agustin Palma Barriga
Jefe del Área de Gestión de Riesgos Químicos
Agencia Española de Seguridad Alimentaria y Nutrición (AESAN)-Ministerio de Consumo
Madrid

SWEDEN - SUÈDE - SUECIA

Dr Viveka Larsson
Principal Regulatory Officer, DVM
Swedish Food Agency
Uppsala

SWITZERLAND - SUISSE - SUIZA

Ms Margrit Abel-kroeker
Scientific Officer
Federal Food Safety and Veterinary Office FSVO
Bern

Mr Mark Stauber
Head Food Hygiene
Federal Food Safety and Veterinary Office FSVO
Bern
SYRIAN ARAB REPUBLIC –
SYRIENNE, RÉP ARABE –
SIRIA, REPÚBLICA ARABE

Dr Ziad Namour
Director of veterinary drugs
Ministry of Agriculture
Damascus

Dr Muhanad Zeater
Chief of quality control lab
Ministry of Agriculture
Damascus

Eng Maisaa Abo Alshamat
Head of Plants standard Department
Syrian Arab organization for standardization and Metrology
Damascus

THAILAND - THAÏLANDE - TAILANDIA

Dr Chantanee Buranathai
Veterinarian, Expert level
Ministry of Agriculture and Cooperatives
Bangkok

Mrs Supanoi Subsinserm
Senior expert in fisheries product quality inspection
Ministry of Agriculture and Cooperatives
Bangkok

Dr Namaporn Attaviroj
Senior Standards Officer
Ministry of Agriculture and Cooperative
Bangkok

Dr Sasi Jaroenpoj
Veterinarian, Expert Level
Ministry of Agriculture and cooperatives
Pathumthani

Mrs Ladda Kaewklapanyacharoen
Medical Scientist senior professional level
Ministry of Public Health
Nonthaburi

Mr Charoen Kaowsuksai
Vice- Chairman
The Federation of Thai Industries
Bangkok

Dr Sakranmanee Krajangwong
Veterinarian, Professional level
Ministry of Agriculture and Cooperative
Bangkok

Dr Mintra Lukkana
Veterinarian, Senior professional level
Ministry of Agriculture and Cooperative
Bangkok

Dr Chaiporn Pumkam
Pharmacist, Senior Professional level
Food and Drug Administration, Ministry of Public Health
Nonthaburi

Dr Julaporn Srinha
Veterinarian, Senior professional level
Ministry of Agriculture and Cooperatives
Pathumthani

Dr Suchana Sukklad
Veterinarian, Professional level
Ministry of Agriculture and Cooperatives
Pathumthani

Ms Naraya Tangsirisap
Veterinarian, Senior Professional Level
Bureau of Quality Control of Livestock Products
Pathumthananee

Dr Kwanhatai Thongpalad
Veterinarian, Senior professional level
Ministry of Agriculture and Cooperative
Bangkok

Ms Wassana Trangjitjing
Officer
Thai Chamber of Commerce
Bangkok

Dr Nanthiya Unprasert
Advisor
Thai Chamber of Commerce
Bangkok

TRINIDAD AND TOBAGO -
TRINITÉ-ET-TOBAGO -
TRINIDAD Y TOBAGO

Dr Saed Rahaman
Director
Ministry of Health
Port-of-Spain

TURKEY - TURQUIE - TURQUÍA

Mrs Nihal Ayse Mortepe
Working group manager
Ministry of Agriculture and Forestry
Ankara

Mrs Ayşe Ayar Kurt
Food engineer
Ministry of Agriculture and Forestry
Ankara

TURKMENISTAN - TURKMÉNISTAN - TURKMENISTÁN

Ms Maya Ashirova
CCP TURKMENISTAN

Mrs Aida Akhmedova
State Inspector of Department of Standards and Certification of State Standard of Turkmenistan
The State Standard of Turkmenistan.

Mr Garif Mullabayev
Programme Assistant
CO WHO TKM

Ms Jeren Myratdurdyyeva
NPO
CO WHO TKM
REP21/RVDF-Appendix I

Mrs Meryem Shamuradova
Sanitary Doctor
Ministry of Health and Medical Industry of Turkmenistan

UGANDA - OUGANDA

Dr Josephine Nanyanzi
Principal Regulatory Officer - Veterinary Medicine
National Drug Authority
Kampala

Ms Ruth Awio
Standards Officer
Uganda National Bureau of Standards
Kampala

Dr Sylvia Baluka
Senior Lecturer
College of Veterinary Medicine, Animal Resources & Biosecurity (COVAB)
Makerere University
Kampala

Dr Moses Matovu
Research Scientist
National Agricultural Research Organization
Kampala

Ms Rehema Meeme
Standards Officer
Uganda National Bureau of Standards
Kampala

Mr Hakim Baligeya Mufumbiro
Principal Standards Officer
Uganda National Bureau of Standards
Kampala

Mr Arthur Mukanga
Standards Officer
Uganda National Bureau of Standards
Kampala

Prof George Nasinyama
Consultant Food Safety
RIMCA
Kampala

Mr Geoffrey Onen
Assistant Commissioner
Directorate of Government Analytical Laboratory
Kampala

UNITED ARAB EMIRATES – ÉMIRATS ARABES UNIS – EMIRATOS ARABES UNIDOS

Ms Sumaiya Abdullah
Food Safety Department
MOIAT

Dr Hanan Afifi
Research & Development
MOIAT

Ms Hajer Alali
Food Safety Department
MOIAT

Ms Dalal Alkatheeri
Specialist
MOIAT

Dr Maryam Alsallagi
Head of studies and Risk assessment Unit
MOIAT

Mr Eyad Attari
Head of Regulatory and Scientific Affairs
MOIAT

Ms Fatma Bakhit
Food
MOIAT

Mr Wael Bani
Food Safety Department
MOIAT

Ms Khadija Eid
Food Control
MOIAT

Mr Vaidehi Garimella
Food Safety Department
MOIAT

Ms Baheiya Mohammad
Food Safety Department
MOIAT

UNITED KINGDOM - ROYAUME-UNI – REINO UNIDO

Dr Kitty Healey
Head of Surveillance Division
Veterinary Medicines Directorate

Mr Sam Fletcher
Head of Human and Environmental Safety Team
Veterinary Medicines Directorate

Ms Egle Gabalyte
Policy Advisor
Department for Environment, Food and Rural Affairs

Mr Callum Harris
Head of Residues Section
Veterinary Medicines Directorate

Mr Mike O’Neill
Head of Codex Policy and Strategy
Food Standards Agency
London

Dr Iulia Turiac
Senior Policy Advisor
Defra
London
UNITED STATES OF AMERICA –
ÉTATS-UNIS D’AMÉRIQUE –
ESTADOSUNIDOS DE AMÉRICA

Ms Brandi Robinson
Program Manager
U.S. Food and Drug Administration
Center for Veterinary Medicine
Rockville, MD

Mr Louis Bluhm
Director, Laboratory Quality Assurance Staff (LQAS)
U.S. Department of Agriculture

Food Safety and Inspection Service
Athens, GA

Ms Trachelle Carr
International Technical Services Specialist
National Pork Producers Council
Washington, DC

Dr Holly Erdely
Pharmacologist
U.S. Food and Drug Administration
Center for Veterinary Medicine
Rockville, MD

Dr Lynn Friedlander
Supervisory Physiologist & Team Leader
U.S. Food and Drug Administration
Rockville, MD

Ms Mallory Gaines
Manager, Market Access and Trade Policy
American Feed Industry Association
Washington DC

Mr Nicholas Gardner
Vice President, Codex and International Regulatory Affairs
U.S. Dairy Export Council
Arlington, VA

Dr Jonathan Greene
Animal Scientist
U.S. Food and Drug Administration
Center for Veterinary Medicine
Rockville, MD

Ms Alexandra Hamilton
International Trade Specialist
United States Department of Agriculture
Washington, DC

Dr Nora Hickey
Liaison
American Veterinary Medical Association
Olympia, WA

Dr Kimon Kanelakis
Pharmacologist
U.S. Food and Drug Administration
Rockville, MD

Ms Rita Kishore
Codex Coordinator
Food and Agriculture Export Alliance
Charlotte, NC

Ms Mary Frances Lowe
U.S. Manager for Codex Alimentarius
U.S. Department of Agriculture
Washington, DC

Dr Matthew Lucia
Director, Office of New Animal Drug Evaluation
U.S. Food and Drug Administration
Rockville, MD

Mrs Margaret Malkoski
Director, Scientific Affairs
National Fisheries Institute
McLean, VA

Dr Dragan Momcilovic
Veterinary Medical Officer
U.S. Food and Drug Administration
Center for Veterinary Medicine
Rockville, MD

Dr Kathryn Simmons
Chief Veterinarian, NCBA
National Cattlemen’s Beef Association
Washington, DC

Mr Vito Su
Food Security Advisor
U.S. Department of State
Washington, DC

Ms Jodi Williams
U.S. Codex, Deputy Manager
U.S. Department of Agriculture
Washington DC

URUGUAY

Ms Maria Natalia Baccino
Asesor IV
Ministry of Livestock, Agriculture and Fisheries
Montevideo

Mrs Natalia Cardozo
Tecnico
Ministerio de Ganadería, Agricultura y Pesca
Montevideo

Mrs Estela Charle
Inspector Veterinario Oficial
Ministerio de Ganadería, Agricultura y Pesca
Montevideo

Mrs Berta Chelle
Encargada depto de Control de Productos Veterinarios
Ministerio de Ganadería, Agricultura y Pesca
Montevideo

Mrs Rossana Diaz
Encargada
Ministerio de Ganadería, Agricultura y Pesca
Montevideo

Mrs Paula Ferrer
Coordinadora de Inocuidad
Ministerio de Ganadería, Agricultura y Pesca
Mr Diego Moreira  
Tecnico  
Ministerio de Ganadería, Agricultura y Pesca  
Montevideo

Mrs María Lizabeth Nogueira  
Encargada  
Laboratorio Microsules  
Montevideo

Mr Gonzalo Suarez  
Profesor Agregado  
Facultad de Veterinaria  
Montevideo

VENEZUELA (BOLIVARIAN REPUBLIC OF) - VENEZUELA (RÉPUBLIQUE BOLIVARIENNE DU) – VENEZUELA (REPÚBLICA BOLIVARIANA DE)

Ms Stephanny Peña  
Coordinadora de Temas Codex  
Servicio Autónomo Nacional de Normalización, Calidad, Metrología y Reglamentos Técnicos (SENCAMER)

Mrs Roxana Abreu  
Líder de Asuntos Internacionales  
Servicio Autónomo Nacional de Normalización, Calidad, Metrología y Reglamentos Técnicos (SENCAMER)

Ms Suzel Arenas  
Médico Veterinario III  
Servicio Autónomo de Contraloría Sanitaria (SACS)

Mrs Nelly Lopez  
Gerente Corporativo de Nutrición y Formulación  
Grupo Calidad

Ms Vanessa Noguera  
Jefe de Nutricion y Formulación  
Grupo Calidad

Mr Julio Rodriguez  
Coordinador de la División de Registros Sanitarios  
Servicio Autónomo de Contraloría Sanitaria (SACS)

Ms Jenitksa Salas  
Jefe de División de Análisis y Desarrollo de Normas  
Servicio Autónomo Nacional de Normalización, Calidad, Metrología y Reglamentos Técnicos (SENCAMER)

VIET NAM

Mrs Thi Bui Oanh Dang  
Official  
Quality Assurance and Testing center 3  
Ho Chi Minh

Mr Tan Viet Dang  
Director  
Ho Chi Minh City University of Food Industry (HUFI)  
Ho Chi Minh

Mrs Thi Hong Tuoi Diep  
Official  
Quality Assurance and Testing center 3  
Ho Chi Minh

Mr Xuan Dieu Duong  
Senior Office  
Department of Science and Technology  
Hanoi

Mrs Huong Quynh Duong  
Official  
Ministry of Industry and Trade  
Hanoi

Mr Thanh Binh Mai  
Quality Manager  
EUROFINS  
Ho Chi Minh

Mrs Thi Minh Tu Nguyen  
Vice Dean  
School of Biotechnology and Food Technology  
Hanoi

Mrs Thi Thao Nguyen  
Deputy Head  
School of Biotechnology and Food Technology  
Hanoi

Mr Huu Vinh Nguyen  
Official  
Quality Assurance and Testing center 3  
Ho Chi Minh

Mr Vu Trung Nguyen  
Official  
National Agro - Forestry - Fisheries Quality Assurance Department - Branch 3

Mrs Thi Hong Nguyen  
Director  
Khue Nam Co.Ltd  
Ho Chi Minh

Mrs Thi Thu Mai Ta  
Official  
Quality Assurance and Testing center 1  
Hanoi

Mrs Nguyen Thi Minh Ha  
Deputy Head  
Vietnam Codex Office  
Hanoi

Mr Vuong Duc Nghia Tran  
Official  
Quality Assurance and Testing center 3  
Ho Chi Minh

ZIMBABWE

Dr Jairus Machakwa  
Director-Veterinary Services  
Ministry of Lands, Agriculture and Rural Resettlement  
Harare
INTERGOVERNMENTAL ORGANIZATIONS -
ORGANISATIONS INTERGOUVERNEMENTALES-
ORGANIZACIONES INTERGUBERNAMENTALES
AFRICAN UNION
Mr John Oppong-Otoo
African Union

INTERNATIONAL NON-GOVERNMENTAL
ORGANIZATIONS -
ORGANISATIONS INTERNATIONALES NON
GOUVERNEMENTALES -
ORGANIZACIONES INTERNACIONALES NO
GUBERNAMENTALES
ECONOMIC COMMUNITY OF WEST AFRICAN STATES
(ECOWAS)
Dr Benoit Gnonlonfin
Senior SPS Advisor
ECOWAS

ASSOCIATION OF AMERICAN FEED CONTROL OFFICIALS
(AAFCO)
Mr Mike Stage
Division Manager
Arkansas Department of Agriculture
Champaign
Mr Richard Ten Eyck
Feed Safety Specialist
Oregon Department of Agriculture
Champaign

INTERNATIONAL CO-OPERATIVE ALLIANCE (ICA)
Mr Yuji Gejo
Officer
International Co-operative Alliance
Mr Kazuo Onitake
Senior Scientist, Quality Assurance Department
International Co-operative Alliance
Tokyo

INTERNATIONAL DAIRY FEDERATION (IDF/FIL)
Dr Jamie Jonker
Chair of the IDF Science and Programme Coordination Committee
International Dairy Federation
Brussels
Mr Ole Madsen
Deputy Chair IDF Standing Committee Residues and Chemical Contaminants
IDF

INTERNATIONAL FEED INDUSTRY FEDERATION (IFIF)
Ms Alexandra De Athayde
Executive Director
International Feed Industry Federation (IFIF)
Wiehl
Ms Leah Wilkinson
Chair, IFIF Regulatory Committee
International Feed Industry Federation (IFIF)
Arlington, VA

THE INTERNATIONAL POULTRY COUNCIL (IPC)
Mr Nicolò Cinotti
Secretary General
International Poultry Council

INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE
Dr Anne Mackenzie
CCP
IFPRI
Mahone Bay

HEALTH FOR ANIMALS (HEALTHFORANIMALS)
Dr Stan Baker
Director, Public Policy and Regulatory Affairs
HealthforAnimals
Dr Alexander Boettner
Exec. Dir. Regulatory Affairs
MSD Animal Health Innovation GmbH
Schwabenheim
Mr Piotr Bonislawski
HealthforAnimals

INTERNATIONAL POULTRY COUNCIL (IPC)
Mr Dennis Erpelding
Science Advisor
International Poultry Council

INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE
Dr Anne Mackenzie
CCP
IFPRI
Mahone Bay

HEALTH FOR ANIMALS (HEALTHFORANIMALS)
Dr Stan Baker
Director, Public Policy and Regulatory Affairs
HealthforAnimals
Dr Alexander Boettner
Exec. Dir. Regulatory Affairs
MSD Animal Health Innovation GmbH
Schwabenheim
Mr Piotr Bonislawski
HealthforAnimals

INTERNATIONAL FEED INDUSTRY FEDERATION (IFIF)
Ms Leah Wilkinson
Chair, IFIF Regulatory Committee
International Feed Industry Federation (IFIF)
Arlington, VA
Dr Maureen Ngoh  
Principal Scientist  
HealthforAnimals

Dr Logeswari Ponnusamy  
HealthforAnimals

Mrs Sabine Schüller  
HealthforAnimals

Mr Jesse Sevcik  
Executive Advisor, Government Affairs  
HealthforAnimals  
Washington, D.C.

Dr Jeff Watts  
HealthforAnimals

Dr Kelly Wynalda Camozzi  
HealthforAnimals

UNITED NATIONS -  
NATIONS UNIES –  
NACIONES UNIDAS

INTERNATIONAL ATOMIC ENERGY AGENCY (IAEA)  
Mr James Jacob Sasanya  
Food Safety Specialist  
IAEA  
Vienna

UNITED NATIONS INDUSTRIAL DEVELOPMENT ORGANIZATION (UNIDO)  
Prof Samuel Godefroy  
Senior Food Regulatory Expert  
UNIDO

FAO  
Ms Daniela Battaglia  
Animal Production Officer  
Food and Agriculture Organization of the United Nations (FAO)

Dr Vittorio Fattori  
Food Safety Officer  
Food and Agriculture Organization of the United Nations (FAO)  
Rome

Ms Eve Fontaine Benedetti  
Legal Adviser  
Food and Agriculture Organization of the United Nations (FAO)

WHO  
Mr Soren Madsen  
Food Safety Officer  
World Health Organization (WHO)

Prof Alan Boobis  
Co-chair of JECFA88 (WHO)

CCRVDF SECRETARIAT  
Mr Kenneth Lowery  
Senior International Issues Analyst  
U.S. Codex Office  
U.S. Department of Agriculture  
Washington DC

Ms Marie Maratos Bhat  
International Issues Analyst  
U.S. Codex Office  
U. S. Department of Agriculture  
Washington, DC

CODEX SECRETARIAT  
Ms Gracia Brisco  
Food Standards Officer  
Codex Alimentarius Commission  
Food and Agriculture Organization of the United Nations (FAO)  
Rome

Ms Verna Carolissen-Mackay  
Food Standards Officer  
Codex Alimentarius Commission  
Food and Agriculture Organization of the United Nations (FAO)  
Rome

Ms Myoengsin Choi  
Food Standards Officer  
Codex Alimentarius Commission  
Food and Agriculture Organization of the United Nations (FAO)  
Rome

Mr David Massey  
Special Adviser - Codex  
Codex Alimentarius Commission  
Food and Agriculture Organization of the United Nations (FAO)  
Rome

Mr Roberto Sciotti  
Consultant  
Codex Alimentarius Commission  
Food and Agriculture Organization of the United Nations (FAO)  
Rome

Mr Giuseppe Di Chiera  
Programme Specialist  
Codex Alimentarius Commission  
Food and Agriculture Organization of the United Nations (FAO)  
Rome

Ms Jocelyne Farruggia  
Codex Alimentarius Commission  
Food and Agriculture Organization of the United Nations (FAO)  
Rome
APPENDIX II

MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS IN FOODS

FLUMETHRIN (HONEY)
(For adoption at Step 8)

FLUMETHRIN (insecticide)

Acceptable Daily Intake

|                | 0–0.004 mg/kg bw based on the NOAEL of 0.37 mg/kg bw per day for skin lesions in parental animals and reduced survival and body-weight gain in pups in a two-generation toxicity study in rats and using a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability). |

Acute Reference dose

|                | 0.005 mg/kg bw based on the NOAEL of 0.5 mg/kg bw for salivation in dams in a developmental toxicity study in rats and using a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability). |

Estimated chronic dietary exposure

|                | 0.008 µg/kg bw per day (for the general population), which represents 0.2% of the upper bound of the ADI. |
|                | 0.006 µg/kg bw per day (for children), which represents 0.2% of the upper bound of the ADI. |

Note: As Flumethrin is also used as pesticide the overall dietary exposure was estimated. The assumptions and detailed results will be displayed in the JECFA85 report. Results below are only for use as veterinary drug.

Estimated Acute Dietary Exposure

|                | 0.1 µg/kg bw per day (for the general population), which represents 2.2% of the ARfD. |
|                | 0.1 µg/kg bw per day (for children), which represents 2.2% of the ARfD. |

Residue Definition

|                | Flumethrin (trans-Z1 and trans Z2 diastereomers at a ratio of approximately 60:40). |

Recommended MRL

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs (µg/kg)</th>
<th>Note</th>
<th>Step</th>
<th>JECFA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Honey</td>
<td>Unnecessary</td>
<td>Residues resulting from the use of this substances as an insecticde in accordance with good practice for veterinary drug are unlikely to pose a hazard to human health.</td>
<td>8</td>
<td>85</td>
<td></td>
</tr>
</tbody>
</table>
**DIFLUBENZURON**  
*(SALMON - MUSCLE PLUS SKIN IN NATURAL PROPORTION)*  
*(For adoption at Step 5/8)*

**DIFLUBENZURON** (insecticide)

| **Acceptable daily intake** | JECFA established an ADI of 0–0.02 mg/kg bw – based on a NOAEL of 2 mg/kg bw per day for increased methaemoglobin and sulphaemoglobin levels in a 2-year study of toxicity and carcinogenicity in rats; and increased methaemoglobin and sulphaemoglobin levels, platelet counts and hepatic pigmentation in a 1-year study of toxicity in dogs – applying a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability). |
| **Acute reference dose** | JECFA reiterated the conclusion of the 81st meeting (1) that it was not necessary to establish an ARfD, in view of the low acute oral toxicity and the absence of developmental toxicity, and any other toxicological effects likely to be elicited by a single dose. |
| **Estimated chronic dietary exposure** | The GECDE for the general population is 0.84 μg/kg bw per day, which represents 4% of the upper bound of the ADI.  
The GECDE for children is 2.85 μg/kg bw per day, which represents 14% of the upper bound of the ADI. |
| **Estimated acute dietary exposure** | The acute dietary exposure was not estimated because JECFA concluded that it was not necessary to establish an ARfD. |
| **Residue definition** | JECFA reconfirmed Diflubenzuron as the marker residue (MR) and the ratio of the MR to the total radioactive residue (TRR) of 0.9 established at its 81st meeting. |
| **Maximum residue limits** | JECFA recommended an MRL in salmon of 10 μg/kg in muscle plus skin in natural proportions. |

**Recommended MRL**

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs (μg/kg) recommended by JECFA88</th>
<th>Step</th>
<th>JECFA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salmon</td>
<td>Muscle plus skin in natural proportions</td>
<td>10</td>
<td>5/8</td>
<td>88</td>
</tr>
</tbody>
</table>
HALQUINOL
(SWINE - MUSCLE, SKIN PLUS FAT, LIVER AND KIDNEY)
(For adoption at Step 5/8)

Acceptable daily intake
JECFA established an ADI of 0–0.2 mg/kg bw, based on histopathological changes in the kidney, accompanied by increases in absolute and relative renal weight in a 1-year chronic toxicity study in rats, applying a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability).

Acute reference dose
JECFA established an ARfD of 0.3 mg/kg bw, based on a NOAEL of 30 mg/kg bw for clinical signs in dams observed in a developmental toxicity study in mice, with application of a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability).

Estimated chronic dietary exposure
The GECDE for the general population is 5.9 µg/kg bw per day, which represents 3% of the upper bound of the ADI.
The GECDE for children is 6.9 µg/kg bw per day, which represents 3.4% of the upper bound of the ADI.

Estimated acute dietary exposure
The GEADE was comparable for children and adults, being 2–224 µg/kg bw per day, which represents 0.5–75% of the ARfD.

Residue definition
The marker residue (MR) is the sum of 5-chloroquinolin-8-ol (5-CL), 5,7-dichloroquinolin-8-ol (5,7-DCL) and their glucuronide metabolites: 5-CLG (expressed as 5-CL equivalents) and 5,7-DCLG (expressed as 5,7-DCL equivalents).

Maximum residue limits
JECFA recommended MRLs in swine of 40 µg/kg for muscle, 350 µg/kg for skin plus fat, 500 µg/kg for liver and 9000 µg/kg for kidney.

Recommended MRLs

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs (µg/kg) recommended by JECFA88</th>
<th>Step</th>
<th>JECFA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swine</td>
<td>Muscle</td>
<td>40</td>
<td>5/8</td>
<td>88</td>
</tr>
<tr>
<td>Swine</td>
<td>Skin plus fat</td>
<td>350</td>
<td>5/8</td>
<td>88</td>
</tr>
<tr>
<td>Swine</td>
<td>Liver</td>
<td>500</td>
<td>5/8</td>
<td>88</td>
</tr>
<tr>
<td>Swine</td>
<td>Kidney</td>
<td>9000</td>
<td>5/8</td>
<td>88</td>
</tr>
</tbody>
</table>
IVERMECTIN
(SHEEP, PIGS AND GOATS – FAT, KIDNEY, LIVER AND MUSCLE)
(For adoption at Step 5)

IVERMECTIN (broad-spectrum antiparasitic agent)

<table>
<thead>
<tr>
<th>Acceptable daily intake</th>
<th>The ADI of 0–10 µg/kg bw established by JECFA81 (1) remains unchanged.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute reference dose</td>
<td>The ARfD of 0.2 mg/kg bw established by JECFA81 remains unchanged.</td>
</tr>
</tbody>
</table>
| Estimated chronic dietary exposure | JECFA established a GECDE for the general population of 0.41 µg/kg bw per day, which represents 4% of the upper bound of the ADI.
JECFA established a GECDE for children of 0.59 µg/kg bw per day, which represents 5.9% of the upper bound of the ADI. |
| Estimated acute dietary exposure | JECFA established a GEADE for the general population of 87 µg/kg bw per day, which represents 43% of the ARfD, from consumption of cattle muscle, and of 1.1 µg/kg bw, which represents 0.6% of the ARfD, from consumption of sheep muscle.
JECFA established a GEADE for children of 82 µg/kg bw per day, which represents 41% of the ARfD, from consumption of cattle muscle and of 1.0 µg/kg bw, which represents 0.5% of the ARfD, from consumption of sheep muscle. |
| Residue definition      | The marker residue (MR) in sheep, pigs and goats is Ivermectin B1a (H2B1a, or 22,23-dihydroavermectin B1a). |
| Maximum residue limits  | JECFA established MRLs for sheep, pigs and goats of 20 µg/kg for fat, 15 µg/kg for kidney, 15 µg/kg for liver and 10 µg/kg for muscle. |

**Recommended MRLs**

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs (µg/kg) recommended by JECFA88</th>
<th>Step</th>
<th>JECFA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sheep, pigs and goats</td>
<td>Fat</td>
<td>20</td>
<td>5</td>
<td>88</td>
</tr>
<tr>
<td>Sheep, pigs and goats</td>
<td>Kidney</td>
<td>15</td>
<td>5</td>
<td>88</td>
</tr>
<tr>
<td>Sheep, pigs and goats</td>
<td>Liver</td>
<td>15</td>
<td>5</td>
<td>88</td>
</tr>
<tr>
<td>Sheep, pigs and goats</td>
<td>Muscle</td>
<td>10</td>
<td>5</td>
<td>88</td>
</tr>
</tbody>
</table>
ZILPATEROL HYDROCHLORIDE
(CATTLE FAT, KIDNEY, LIVER, MUSCLE)
(At Step 4)
(for advice/decision by CCEXEC/CAC
REP21/RVDF, paragraph 87)

ZILPATEROL HYDROCHLORIDE (β2-adrenoceptor agonist)

<table>
<thead>
<tr>
<th>Acceptable daily intake</th>
<th>ADI is 0-0.04 μg/kg bw established at JECFA78 (WHO TRS No. 988, 2014) and reaffirmed at JECFA81 (2015) and JECFA85 (2017).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute reference dose</td>
<td>ARFD is 0.04 μg/kg bw based on a lowest-observed-adverse-effect level (LOAEL) of 0.76 μg/kg bw for acute pharmacological effects observed in a single-dose human study, with application of an uncertainty factor of 20, comprising a default uncertainty factor of 10 for human individual variability and an additional uncertainty factor of 2 to account for use of a LOAEL for a slight effect instead of a NOAEL (JECFA81).</td>
</tr>
<tr>
<td>Estimated acute dietary exposure</td>
<td>GEADE is 1.9 μg/day for the general population, which represents approximately 80% of the ARFD. The GEADE is 0.57 μg/day for children, which represents approximately 94% of the ARFD (JECFA81).</td>
</tr>
<tr>
<td>Residue Definition</td>
<td>Zilpaterol (free base) in muscle, liver and kidney.</td>
</tr>
</tbody>
</table>

**Recommended MRLs**

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs (µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Kidney</td>
<td>3.3</td>
<td>4</td>
<td>81, 85</td>
</tr>
<tr>
<td>Cattle</td>
<td>Liver</td>
<td>3.5</td>
<td>4</td>
<td>81, 85</td>
</tr>
<tr>
<td>Cattle</td>
<td>Muscle</td>
<td>0.5</td>
<td>4</td>
<td>81, 85</td>
</tr>
</tbody>
</table>
ANNEX C: APPROACH FOR THE EXTRAPOLATION OF MAXIMUM RESIDUE LIMITS OF VETERINARY DRUGS TO ONE OR MORE SPECIES

General criteria for extrapolation:

1. Extrapolation should take place only between the same tissues/food commodities in the reference and concerned species (e.g. muscle to muscle, fat to fat etc.).

2. Extrapolation of reference species MRLs to a concerned species on a one to one basis should be considered only if all of the following are satisfied:
   (i) the reference and concerned species are related (see “A note on terminology” below),
   (ii) the marker residue in the reference species is the parent compound only, or is the same as the total residues of toxicological concern, or the Codex MRL status in the reference species is ‘unnecessary’ and there is an expectation that the active substance will be used under the same conditions (i.e. by the same administration routes and at similar doses) in both species.
   (iii) the M:T\(^1\) (the marker ‘M’ to total residues of toxicological concern ‘T’) established for the reference species can be applied to the concerned species.

Specific criteria for extrapolation

3. In order to ensure that the third of the above-mentioned three general criteria is satisfied, the following specific criteria are proposed.
   (i) Where identical Codex MRLs have been established in at least two related species on the basis of JECFA recommendations or there is good reason to consider extrapolation from just one related species, these Codex MRLs can be extrapolated to other related species (e.g. extrapolate from cattle and sheep to all ruminants).

   \(\text{Explanatory note: The existence of identical MRLs in two related species provides grounds upon which to base the assumption that metabolism does not vary significantly within the group of related species—i.e. that the M:T established for the reference species can be applied to the concerned species.}\)

   (ii) Where identical M:T values have been used in JECFA calculations for two related species but the MRLs recommended (by JECFA) differ, the most conservative set of Codex MRLs (i.e. the MRLs from the species associated with the lowest consumer exposure estimate) can be extrapolated to other related species (e.g. where different MRL values have been established for cattle and sheep and extrapolation is considered to goats, the lowest set of MRLs should be used for extrapolation).

   \(\text{Explanatory note: The fact that JECFA considered it appropriate to use identical M:T values in two related species provides grounds upon which to base the assumption that metabolism does not vary significantly within the group of related species—i.e. that the M:T established for the reference species can be applied to the concerned species.}\)

   (iii) Where the M:T established by JECFA is 1 in all tissues in a single reference species, the same Codex MRLs can be extrapolated to related species.

   \(\text{Explanatory note: The fact that the M:T is 1 in all tissues/food commodities indicates that the marker residue includes all the compounds of concern. It is considered reasonable to assume that this would also be the case in the concerned species.}\)

\(^1\) EHC 240 (1) defines the marker residue as: The parent drug, or any of its metabolites, or a combination of any of these, with a known relationship to the concentration of the total residue in each of the various edible tissues at any time between administration of the drug and the depletion of residues to safe levels. Where ‘total residues of toxicological concern’ are not defined, ‘total residue’ may be used where ‘Total residue’ is defined CXA 5-1993 (2): the total residue of a drug in animal derived food consists of the parent drug together with all the metabolites and drug based products in the food after administration of the drug to food producing animals. The amount of total residues is generally determined by means of a study using the radiolabelled drug, and is expressed as the parent drug equivalent in mg/kg of the food’.
Finally, while the above criteria can be used in all cases, the following additional criteria are proposed for fish, milk and eggs (i.e. extrapolation for fish, milk and eggs may be based on the above criteria OR based on the additional criteria below):

(iv) For fish, where the MRL in muscle/fillet recommended by JECFA was established based on the limit of quantification (LoQ) (e.g., twice the LoQ), the Codex MRL can be extrapolated to all bony fish.

**Explanatory note:** The fact that the MRL in muscle/fillet is below the LoQ indicates that residues in muscle/fillet are not measurable and so do not make a significant contribution to the intake calculation. Even if there are differences in metabolism between fish species, the possibility that they will be so dramatic as to result in a level of residues in muscle/fillet sufficiently high to significantly impact on overall consumer exposure is considered unrealistic.

(v) For milk and eggs, where the M:T established by JECFA is 1 (in milk or eggs of a reference species), the milk/egg Codex MRL of the reference species can be extrapolated to milk of other ruminants and eggs of other domesticated poultry species, respectively, even if the M:T is not 1 in tissues.

**Explanatory note:** For milk and eggs, there may be a concern that the fat content differs between related species. However, if the M:T is 1 in the reference species this indicates that the M:T is not significantly influenced by the fat content.

### A note on terminology

- ‘Reference species’ is used to refer to a species in which Codex MRLs have been established based on a scientific evaluation by JECFA
- ‘Concerned species’ is used to refer to a species for which extrapolation is being considered
- ‘Related species’ means species belonging to the same category of food producing species of ruminant and non-ruminant mammals*, birds or fin fish**
- ‘Unrelated species’ is used to refer to species belonging to different categories of food producing species

* The category of non-ruminant food producing mammals is considered to include pigs, horses and rabbits
** Three distinct classes of fish are usually identified: (i) jawless fish (Agnatha), (ii) cartilaginous fish (Chondrichytes) and (iii) finfish. To date, MRL data have been provided only for finfish, and it is these that are predominantly farmed and eaten. Consequently, it is proposed that MRL extrapolations in fish should be limited to this class.

### Reporting extrapolated MRLs

4. Where CCRVDF agrees to extrapolate MRLs, it should be clear that these MRLs were established by extrapolation rather than on the basis of a substance/species specific JECFA assessment. An appropriate symbol should be included next the relevant values reported in the MRL database. Moreover, extrapolated MRLs should be reconsidered in case the reference MRLs are modified or new data/information on the active substance in question becomes available.

---

**Part B**

Amendment to paragraph 30 of the *Risk Analysis Principles Applied by the Codex Committee on Residues of Veterinary Drugs in Food*  
(Consequential amendment for adoption)

A footnote in paragraph 30 of the Risk Analysis Principles – 2nd bullet point:

Approach for the extrapolation of MRLs of veterinary drugs to one or more species is presented in Annex C to these principles
Edible offal: Those parts of an animal, apart from the skeletal muscle, fat and attached skin, that are considered fit for human consumption.
PRINCIPLES AND APPROACH TO THE PARALLEL REVIEW
OF A NEW VETERINARY DRUG BY JECFA AND REGULATORY AGENCIES

(For reference by CCRVDF)

Principles

The following principles, as is the case during any scientific review by JECFA, should be observed:

1. **Transparency.** Nominating member country and drug sponsor should identify if a veterinary drug is intended for a parallel process and be open about dossier submission timeframes.

2. **Confidentiality.** Much of the data submitted to JECFA or national regulator(s) is confidential and there is a good precedent to respect the confidentiality of the data.

3. **Independence.** The national authorization process and JECFA process are two separate independent processes and subject to their own independent decisions and therefore are not contingent on one another.

Process

The proposed phases of the process are:

**Phase 1: Identification of a candidate**

A product is identified by a drug sponsor and during bilateral discussions with a member country(ies), the product is identified as a candidate. The current Priority List nomination requirements of a veterinary drug would also apply to a JECFA parallel review process. The Risk Analysis Principles Applied by the CCRVDF lists criteria required for a veterinary drug to appear on the Priority List. A proposed veterinary drug shall meet some or all of the following criteria:

- “A Member has proposed the compound for evaluation (a template for information recommended for consideration in the priority list by Codex Committee on Residues of Veterinary Drugs in Foods has been completed and be available to the Committee);
- “A Member has established good veterinary practices with regard to the compound;
- “The compound has the potential to cause public health and/or international trade problems;
- “The compound is available as a commercial product; and
- “There is a commitment that a dossier will be made available.”

**Phase 2: Submission**

A product is submitted (or is expected to be submitted) to a national regulatory authority, most likely in one of the larger markets (in practice, most veterinary products are first submitted for review in the U.S. or in Europe). At the following CCRVDF meeting, the product would be submitted (by the Codex Member who received the product application or is expected to receive the application by a certain date) for inclusion on the priority list at CCRVDF (Step 1).

**Phase 3: Assessment**

JECFA and the national assessor follow their normal processes of assessing the product. (Step 2).

**Phase 4: Consideration by CCRVDF**

Draft ADI and MRLs proposed by JECFA and circulated for comment (Step 3).

The remainder of the uniform procedures for the elaboration of Codex standards and related texts would be followed, consistent with the current process.

---

1 The discussion paper on the parallel review of a new veterinary drug by JECFA and regulatory agencies can be downloaded from the Codex website (CX/RVDF 21/25/10):

### PRIORITY LIST OF VETERINARY DRUGS

(Parts I and V for approval by CAC44, Part II for action by CCRVDF26 and Parts III and IV for follow-up by JECFA)

<table>
<thead>
<tr>
<th>Name of Compound</th>
<th>Question(s) to be answered</th>
<th>Registration status</th>
<th>Proposed by</th>
<th>Comments</th>
<th>When will data package be available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imidacloprid</td>
<td>Request for MRL for fin fish in muscle and skin in natural proportions.</td>
<td>Nominator notes that relevant MRLs are established in the EU.</td>
<td>Norway</td>
<td>ADI set by JMPR at 0-0.06 mg/kg bw (2001), ARfD 0.4 mg/kg bw (2002).</td>
<td>Residue and toxicological data available July 2021.</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>Request for re-evaluation of MRLs for sheep, goat ad pig tissues.</td>
<td>MRLs are established in many countries.</td>
<td>EU</td>
<td>ADI set by JECFA at 0-10 μg/kg bw (2015), ARfD 0.2 mg/kg bw (2015).</td>
<td>Residue data on sheep are available.</td>
</tr>
<tr>
<td>Nicarbazin</td>
<td>Request re-evaluation of MRLs for chicken tissues</td>
<td>Nominator notes that relevant MRLs are established in many countries.</td>
<td>Argentina/Malaysia</td>
<td>ADI set by JECFA at 0-0.4 mg/kg bw (1998).</td>
<td>Residue data available July 2021.</td>
</tr>
</tbody>
</table>
## Part II. Veterinary drugs for which data availability should be confirmed at the next CCRVDF

<table>
<thead>
<tr>
<th>Name of Compound</th>
<th>Question(s) to be answered</th>
<th>Proposed by</th>
<th>Comments</th>
<th>When will data package be available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin</td>
<td>Request for MRLs for chicken tissues.</td>
<td>Chile</td>
<td>ADI set by JECFA at 0-0.07 μg/kg bw (2011), ARfd 0.005 mg/kg bw (2017). Classified by WHO as a CIA and by the OIE as VCIA.</td>
<td>Residue data expected available July 2024.</td>
</tr>
<tr>
<td>Ethoxyquin (feed additive use)</td>
<td>Request to establish MRL in shrimp muscle.</td>
<td>Philippines/India</td>
<td>Carried over from CCRVDF21 (2013). ADI 0-0.005 mg/kg bw (2005 JMPR). The ADI and the ARfd are applicable to ethoxyquin and its metabolites/degradation products methylethoxyquin (MEQ), dihydroethoxyquin (DHEQ), dehydromethylethoxyquin (DHMEQ) ARfd 0.5 mg/kg bw (2005 JMPR).</td>
<td>India advised data are being generated.</td>
</tr>
<tr>
<td>Norfloxacin</td>
<td>Request to establish MRLs for cattle, camels, equines, goats, poultry, sheep and swine tissues.</td>
<td>Peru</td>
<td>Norfloxacin is classified by WHO as a CIA and by the OIE as a veterinary CIA.</td>
<td>Peru to advise at next CRVDF if data are available.</td>
</tr>
<tr>
<td>Name of Compound</td>
<td>Information required by JECFA</td>
<td>Comments</td>
<td>When will data package be available</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------------</td>
<td>----------</td>
<td>-----------------------------------</td>
<td></td>
</tr>
<tr>
<td>Ethion</td>
<td>Additional data/scientific argument to enable MR and MR:TRR to be determined, analytical method.</td>
<td>Argentina (Costa Rica, Uruguay)</td>
<td>From JECFA85, ADI 0-0.002 mg/kg bw, ARfD 0.02 mg/kg bw for general population and 0.002 mg/kg bw for women of child-bearing age.</td>
<td>Metabolism studies to identify compounds of concern, validation of an analytical method and a radiolabel study to enable MR and MR:TRR to be determined are expected to be completed in 2024.</td>
</tr>
<tr>
<td>Flumethrin</td>
<td>Additional data/scientific argument to enable MR and MR:TRR to be determined, residue depletion data, identity of metabolite in milk and toxicological profile.</td>
<td>EU</td>
<td>ADI set by JECFA at 0-0.004 mg/kg bw (2017), ARfD 0.005 mg/kg bw (2017).</td>
<td>Additional data not expected to be available for 3-4 years.</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>Additional data/scientific argument to enable a mADI to be set, additional data/scientific argument to enable MR and MR:TRR to be determined, analytical method.</td>
<td>Argentina/Paraguay</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Part IV. Parallel review – Evaluation of a new compound

<table>
<thead>
<tr>
<th>Name of Compound</th>
<th>Information required by JECFA</th>
<th>Comments</th>
<th>When will data package be available</th>
</tr>
</thead>
</table>
| Selamectin       | Additional data/scientific argument to enable MR and MR:TRR to be determined, analytical method, information on GVP, stability of radiolabel in tissues. | Sponsor intends to submit:  
- Characterization of the residues in tissues in order to establish an MR:TRR.  
- An MR depletion study under conditions of use, conducted in a laboratory.  
- Information on an analytical method suitable for monitoring purposes.  
- Information on the proposed withdrawal period.  
- Confirmation of the stability of the radiolabel in tissues.  

### Part V Compounds for which CCRDVF will consider extrapolation of Codex MRLs to additional species

<table>
<thead>
<tr>
<th>Name of compound</th>
<th>Extrapolation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>Goat and sheep milk</td>
</tr>
</tbody>
</table>